Chemotherapy - Related Links
Open Access Articles- Top Results for Chemotherapy
Journal of Cancer Science & TherapyCombining Systemic Therapies with Radiation in Non-Small Cell Lung Cancer
Journal of Gastrointestinal & Digestive SystemSynchronous Liver Resection with Cytoreductive Surgery for the Treatment of Liver and Peritoneal Metastases from Colon Cancer: Results from an Austra
Journal of Blood Disorders & TransfusionDifferential Interactions of Falcarinol Combined with Anti-Tumour Agents on Cellular Proliferation and Apoptosis in Human Lymphoid Leukaemia Cell Line
Chemotherapy: Open AccessHistorical Perspectives of Drug Treatments in Cancer Quackery
Journal of Nuclear Medicine & Radiation TherapyAssessment of Sorafenib and AntiVEGF Combination Therapy Response which Added to Neoadjuvant Therapy in two Pediatric Metastatic Ewing Sarcoma Patient
This page is a soft redirect.Antimicrobial chemotherapy]].
Chemotherapy (often abbreviated to chemo and sometimes CTX or CTx) is a category of cancer treatment that uses chemical substances, especially one or more anti-cancer drugs (chemotherapeutic agents) that are given as part of a standardized chemotherapy regimen. Chemotherapy may be given with a curative intent, or it may aim to prolong life or to reduce symptoms (palliative chemotherapy). Along with hormonal therapy and targeted therapy, it is one of the major categories of medical oncology (pharmacotherapy for cancer). These modalities are often used in conjunction with other cancer treatments, such as radiation therapy, surgery, and/or hyperthermia therapy. Some chemotherapy drugs are also used to treat other conditions, including AL amyloidosis, ankylosing spondylitis, multiple sclerosis, Crohn's disease, psoriasis, psoriatic arthritis, systemic lupus erythematosus, rheumatoid arthritis, and scleroderma.
Traditional chemotherapeutic agents are cytotoxic, that is to say they act by killing cells that divide rapidly, one of the main properties of most cancer cells. This means that chemotherapy also harms cells that divide rapidly under normal circumstances: cells in the bone marrow, digestive tract, and hair follicles. This results in the most common side-effects of chemotherapy: myelosuppression (decreased production of blood cells, hence also immunosuppression), mucositis (inflammation of the lining of the digestive tract), and alopecia (hair loss).
Some newer anticancer drugs (for example, various monoclonal antibodies) are not indiscriminately cytotoxic, but rather target proteins that are abnormally expressed in cancer cells and that are essential for their growth. Such treatments are often referred to as targeted therapy (as distinct from classic chemotherapy) and are often used alongside traditional chemotherapeutic agents in antineoplastic treatment regimens.
Chemotherapy may use one drug at a time (single-agent chemotherapy) or several drugs at once (combination chemotherapy or polychemotherapy). The combination of chemotherapy and radiotherapy is chemoradiotherapy. Chemotherapy using drugs that convert to cytotoxic activity only upon light exposure is called photochemotherapy or photodynamic therapy.
- 1 History
- 2 General mode of action in cancer
- 3 Types
- 4 Treatment strategies
- 5 Dosage
- 6 Delivery
- 7 Adverse effects
- 7.1 Immunosuppression and myelosuppression
- 7.2 Typhlitis
- 7.3 Gastrointestinal distress
- 7.4 Anemia
- 7.5 Fatigue
- 7.6 Nausea and vomiting
- 7.7 Hair loss
- 7.8 Secondary neoplasm
- 7.9 Infertility
- 7.10 Teratogenicity
- 7.11 Peripheral neuropathy
- 7.12 Cognitive impairment
- 7.13 Tumor lysis syndrome
- 7.14 Organ damage
- 7.15 Other side-effects
- 8 Limitations
- 9 Efficacy
- 10 Resistance
- 11 Cytotoxics and targeted therapies
- 12 Newer and experimental approaches
- 13 Other uses
- 14 Occupational precautions
- 15 In other animals
- 16 Comparison of available agents
- 17 Sales
- 18 See also
- 19 References
- 20 Bibliography
- 21 External links
The first use of drugs to treat cancer was in the early 20th century, although it was not originally intended for that purpose. Mustard gas was used as a chemical warfare agent during World War I and was discovered to be a potent suppressor of hematopoiesis (blood production). A similar family of compounds known as nitrogen mustards were studied further during World War II at the Yale School of Medicine. It was reasoned that an agent that damaged the rapidly growing white blood cells might have a similar effect on cancer. Therefore, in December 1942, several patients with advanced lymphomas (cancers of the lymphatic system and lymph nodes) were given the drug by vein, rather than by breathing the irritating gas. Their improvement, although temporary, was remarkable. Concurrently, during a military operation in World War II, following a German air raid on the Italian harbour of Bari, several hundred people were accidentally exposed to mustard gas, which had been transported there by the Allied forces to prepare for possible retaliation in the event of German use of chemical warfare. The survivors were later found to have very low white blood cell counts. After WWII was over and the reports declassified, the experiences converged and led researchers to look for other substances that might have similar effects against cancer. The first chemotherapy drug to be developed from this line of research was mustine. Since then, many other drugs have been developed to treat cancer, and drug development has exploded into a multibillion-dollar industry, although the principles and limitations of chemotherapy discovered by the early researchers still apply.
The term chemotherapy
The word chemotherapy without a modifier usually refers to cancer treatment, but its historical meaning was broader. The term was coined in the early 1900s by Paul Ehrlich as meaning any use of chemicals to treat any disease (chemo- + -therapy), such as the use of antibiotics (antibacterial chemotherapy). Ehrlich was not optimistic that effective chemotherapy drugs would be found for the treatment of cancer. The first modern chemotherapeutic agent was arsphenamine, an arsenic compound discovered in 1907 and used to treat syphilis. This was later followed by sulfonamides (sulfa drugs) and penicillin. In today's usage, the sense "any treatment of disease with drugs" is often expressed with the word pharmacotherapy.
General mode of action in cancer
Cancer is the uncontrolled growth of cells coupled with malignant behaviour: invasion and metastasis (among other features). It is caused by the interaction between genetic susceptibility and environmental factors. These factors lead to accumulations of genetic mutations in oncogenes (genes that control the growth rate of cells) and tumor suppressor genes (genes that help to prevent cancer), which gives cancer cells their malignant characteristics, such as uncontrolled growth.
In the broad sense, most chemotherapeutic drugs work by impairing mitosis (cell division), effectively targeting fast-dividing cells. As these drugs cause damage to cells, they are termed cytotoxic. They prevent mitosis by various mechanisms including damaging DNA and inhibition of the cellular machinery involved in cell division. One theory as to why these drugs kill cancer cells is that they induce a programmed form of cell death known as apoptosis.
As chemotherapy affects cell division, tumors with high growth rates (such as acute myelogenous leukemia and the aggressive lymphomas, including Hodgkin's disease) are more sensitive to chemotherapy, as a larger proportion of the targeted cells are undergoing cell division at any time. Malignancies with slower growth rates, such as indolent lymphomas, tend to respond to chemotherapy much more modestly. Heterogeneic tumours may also display varying sensitivities to chemotherapy agents, depending on the subclonal populations within the tumor.
Alkylating agents are the oldest group of chemotherapeutics in use today. Originally derived from mustard gas used in World War I, there are now many types of alkylating agents in use. They are so named because of their ability to alkylate many molecules, including proteins, RNA and DNA. This ability to bind covalently to DNA via their alkyl group is the primary cause for their anti-cancer effects. DNA is made of two strands and the molecules may either bind twice to one strand of DNA (intrastrand crosslink) or may bind once to both strands (interstrand crosslink). If the cell tries to replicate crosslinked DNA during cell division, or tries to repair it, the DNA strands can break. This leads to a form of programmed cell death called apoptosis. Alkylating agents will work at any point in the cell cycle and thus are known as cell cycle-independent drugs. For this reason the effect on the cell is dose dependent; the fraction of cells that die is directly proportional to the dose of drug.
The subtypes of alkylating agents are the nitrogen mustards, nitrosoureas, tetrazines, aziridines, cisplatins and derivatives, and non-classical alkylating agents. Nitrogen mustards include mechlorethamine, cyclophosphamide, melphalan, chlorambucil, ifosfamide and busulfan. Nitrosoureas include N-Nitroso-N-methylurea (MNU), carmustine (BCNU), lomustine (CCNU) and semustine (MeCCNU), fotemustine and streptozotocin. Tetrazines include dacarbazine, mitozolomide and temozolomide. Aziridines include thiotepa, mytomycin and diaziquone (AZQ). Cisplatin and derivatives include cisplatin, carboplatin and oxaliplatin. They impair cell function by forming covalent bonds with the amino, carboxyl, sulfhydryl, and phosphate groups in biologically important molecules. Non-classical alkylating agents include procarbazine and hexamethylmelamine.
Anti-metabolites are a group of molecules that impede DNA and RNA synthesis. Many of them have a similar structure to the building blocks of DNA and RNA. The building blocks are nucleotides; a molecule comprising a nucleobase, a sugar and a phosphate group. The nucleobases are divided into purines (guanine and adenine) and pyrimidines (cytosine, thymine and uracil). Anti-metabolites resemble either nucleobases or nucleosides (a nucleotide without the phosphate group), but have altered chemical groups. These drugs exert their effect by either blocking the enzymes required for DNA synthesis or becoming incorporated into DNA or RNA. By inhibiting the enzymes involved in DNA synthesis, they prevent mitosis because the DNA cannot duplicate itself. Also, after misincorporation of the molecules into DNA, DNA damage can occur and programmed cell death (apoptosis) is induced. Unlike alkylating agents, anti-metabolites are cell cycle dependent. This means that they only work during a specific part of the cell cycle, in this case S-phase (the DNA synthesis phase). For this reason, at a certain dose, the effect plateaus and proportionally no more cell death occurs with increased doses. Subtypes of the anti-metabolites are the anti-folates, fluoropyrimidines, deoxynucleoside analogues and thiopurines.
The anti-folates include methotrexate and pemetrexed. Methotrexate inhibits dihydrofolate reductase (DHFR), an enzyme that regenerates tetrahydrofolate from dihydrofolate. When the enzyme is inhibited by methotrexate, the cellular levels of folate coenzymes diminish. These are required for thymidylate and purine production, which are both essential for DNA synthesis and cell division. Pemetrexed is another anti-metabolite that affects purine and pyrimidine production, and therefore also inhibits DNA synthesis. It primarily inhibits the enzyme thymidylate synthase, but also has effects on DHFR, aminoimidazole carboxamide ribonucleotide formyltransferase and glycinamide ribonucleotide formyltransferase. The fluoropyrimidines include fluorouracil and capecitabine. Fluorouracil is a nucleobase analogue that is metabolised in cells to form at least two active products; 5-fluourouridine monophosphate (FUMP) and 5-fluoro-2'-deoxyuridine 5'-phosphate (fdUMP). FUMP becomes incorporated into RNA and fdUMP inhibits the enzyme thymidylate synthase; both of which lead to cell death. Capecitabine is a prodrug of 5-fluorouracil that is broken down in cells to produce the active drug. The deoxynucleoside analogues include cytarabine, gemcitabine, decitabine, Vidaza, fludarabine, nelarabine, cladribine, clofarabine and pentostatin. The thiopurines include thioguanine and mercaptopurine.
Anti-microtubule agents are plant-derived chemicals that block cell division by preventing microtubule function. Microtubules are an important cellular structure composed of two proteins; α-tubulin and β-tubulin. They are hollow rod shaped structures that are required for cell division, among other cellular functions. Microtubules are dynamic structures, which means that they are permanently in a state of assembly and disassembly. Vinca alkaloids and taxanes are the two main groups of anti-microtubule agents, and although both of these groups of drugs cause microtubule dysfunction, their mechanisms of action are completely opposite. The vinca alkaloids prevent the formation of the microtubules, whereas the taxanes prevent the microtubule disassembly. By doing so, they prevent the cancer cells from completing mitosis. Following this, cell cycle arrest occurs, which induces programmed cell death (apoptosis). Also, these drugs can affect blood vessel growth; an essential process that tumours utilise in order to grow and metastasise.
Vinca alkaloids are derived from the Madagascar periwinkle, Catharanthus roseus (formerly known as Vinca rosea). They bind to specific sites on tubulin, inhibiting the assembly of tubulin into microtubules. The original vinca alkaloids are completely natural chemicals that include vincristine and vinblastine. Following the success of these drugs, semi-synthetic vinca alkaloids were produced: vinorelbine, vindesine, and vinflunine. These drugs are cell cycle-specific. They bind to the tubulin molecules in S-phase and prevent proper microtubule formation required for M-phase.
Taxanes are natural and semi-synthetic drugs. The first drug of their class, paclitaxel, was originally extracted from the Pacific Yew tree, Taxus brevifolia. Now this drug and another in this class, docetaxel, are produced semi-synthetically from a chemical found in the bark of another Yew tree; Taxus baccata. These drugs promote microtubule stability, preventing their disassembly. Paclitaxel prevents the cell cycle at the boundary of G2-M, whereas docetaxel exerts its effect during S-phase. Taxanes present difficulties in formulation as medicines because they are poorly soluble in water.
Podophyllotoxin is an antineoplastic lignan obtained primarily from the American Mayapple (Podophyllum peltatum) and Himalayan Mayapple (Podophyllum hexandrum or Podophyllum emodi). It has anti-microtubule activity, and its mechanism is similar to that of vinca alkaloids in that they bind to tubulin, inhibiting microtubule formation. Podophyllotoxin is used to produce two other drugs with different mechanisms of action: etoposide and teniposide.
Topoisomerase inhibitors are drugs that affect the activity of two enzymes: topoisomerase I and topoisomerase II. When the DNA double-strand helix is unwound, during DNA replication or transcription, for example, the adjacent unopened DNA winds tighter (supercoils), like opening the middle of a twisted rope. The stress caused by this effect is in part aided by the topoisomerase enzymes. They produce single- or double-strand breaks into DNA, reducing the tension in the DNA strand. This allows the normal unwinding of DNA to occur during replication or transcription. Inhibition of topoisomerase I or II interferes with both of these processes.
Two topoisomerase I inhibitors, irinotecan and topotecan, are semi-synthetically derived from camptothecin, which is obtained from the Chinese ornamental tree Camptotheca acuminata. Drugs that target topoisomerase II can be divided into two groups. The topoisomerase II poisons cause increased levels enzymes bound to DNA. This prevents DNA replication and transcription, causes DNA strand breaks, and leads to programmed cell death (apoptosis). These agents include etoposide, doxorubicin, mitoxantrone and teniposide. The second group, catalytic inhibitors, are drugs that block the activity of topoisomerase II, and therefore prevent DNA synthesis and translation because the DNA cannot unwind properly. This group includes novobiocin, merbarone, and aclarubicin, which also have other significant mechanisms of action.
The cytotoxic antibiotics are a varied group of drugs that have various mechanisms of action. The group includes the anthracyclines and other drugs including actinomycin, bleomycin, plicamycin, and mitomycin. Doxorubicin and daunorubicin were the first two anthracyclines, and were obtained from the bacterium Streptomyces peucetius. Derivatives of these compounds include epirubicin and idarubicin. Other clinically used drugs in the anthracyline group are pirarubicin, aclarubicin, and mitoxantrone. The mechanisms of anthracyclines include DNA intercalation (molecules insert between the two strands of DNA), generation of highly reactive free radicals that damage intercellular molecules and topoisomerase inhibition. Actinomycin is a complex molecule that intercalates DNA and prevents RNA synthesis. Bleomycin, a glycopeptide isolated from Streptomyces verticillus, also intercalates DNA, but produces free radicals that damage DNA. This occurs when bleomycin binds to a metal ion, becomes chemically reduced and reacts with oxygen. Mitomycin is a cytotoxic antibiotic with the ability to alkylate DNA.
|Breast cancer||Cyclophosphamide, methotrexate, 5-fluorouracil||CMF|
|Hodgkin's disease||Mustine, vincristine, procarbazine, prednisolone||MOPP|
|Doxorubicin, bleomycin, vinblastine, dacarbazine||ABVD|
|Non-Hodgkin's lymphoma||Cyclophosphamide, doxorubicin, vincristine, prednisolone||CHOP|
|Germ cell tumor||Bleomycin, etoposide, cisplatin||BEP|
|Stomach cancer||Epirubicin, cisplatin, 5-fluorouracil||ECF|
|Epirubicin, cisplatin, capecitabine||ECX|
|Bladder cancer||Methotrexate, vincristine, doxorubicin, cisplatin||MVAC|
|Lung cancer||Cyclophosphamide, doxorubicin, vincristine,||CAV|
|Colorectal cancer||5-fluorouracil, folinic acid, oxaliplatin||FOLFOX|
- Combined modality chemotherapy is the use of drugs with other cancer treatments, such as radiation therapy, surgery and/or hyperthermia therapy.
- Induction chemotherapy is the first line treatment of cancer with a chemotherapeutic drug. This type of chemotherapy is used for curative intent.
- Consolidation chemotherapy is given after remission in order to prolong the overall disease-free time and improve overall survival. The drug that is administered is the same as the drug that achieved remission.
- Intensification chemotherapy is identical to consolidation chemotherapy but a different drug than the induction chemotherapy is used.
- Combination chemotherapy involves treating a patient with a number of different drugs simultaneously. The drugs differ in their mechanism and side-effects. The biggest advantage is minimising the chances of resistance developing to any one agent. Also, the drugs can often be used at lower doses, reducing toxicity.
- Neoadjuvant chemotherapy is given prior to a local treatment such as surgery, and is designed to shrink the primary tumor. It is also given to cancers with a high risk of micrometastatic disease.
- Adjuvant chemotherapy is given after a local treatment (radiotherapy or surgery). It can be used when there is little evidence of cancer present, but there is risk of recurrence. It is also useful in killing any cancerous cells that have spread to other parts of the body. These micrometastases can be treated with adjuvant chemotherapy and can reduce relapse rates caused by these disseminated cells.
- Maintenance chemotherapy is a repeated low-dose treatment to prolong remission.
- Salvage chemotherapy or palliative chemotherapy is given without curative intent, but simply to decrease tumor load and increase life expectancy. For these regimens, in general, a better toxicity profile is expected.
All chemotherapy regimens require that the patient be capable of undergoing the treatment. Performance status is often used as a measure to determine whether a patient can receive chemotherapy, or whether dose reduction is required. Because only a fraction of the cells in a tumor die with each treatment (fractional kill), repeated doses must be administered to continue to reduce the size of the tumor. Current chemotherapy regimens apply drug treatment in cycles, with the frequency and duration of treatments limited by toxicity to the patient.
Dosage of chemotherapy can be difficult: If the dose is too low, it will be ineffective against the tumor, whereas, at excessive doses, the toxicity (side-effects) will be intolerable to the patient. The standard method of determining chemotherapy dosage is based on calculated body surface area (BSA). The BSA is usually calculated with a mathematical formula or a nomogram, using a patient's weight and height, rather than by direct measurement of body mass. This formula was originally derived in a 1916 study and attempted to translate medicinal doses established with laboratory animals to equivalent doses for humans. The study only included 9 human subjects. When chemotherapy was introduced in the 1950s, the BSA formula was adopted as the official standard for chemotherapy dosing for lack of a better option.
Recently, the validity of this method in calculating uniform doses has been questioned. The reason for this is that the formula only takes into account the individual's weight and height. Drug absorption and clearance are influenced by multiple factors, including age, gender, metabolism, disease state, organ function, drug-to-drug interactions, genetics, and obesity, which has a major impact on the actual concentration of the drug in the patient's bloodstream. As a result, there is high variability in the systemic chemotherapy drug concentration among patients dosed by BSA, and this variability has been demonstrated to be more than 10-fold for many drugs. In other words, if two patients receive the same dose of a given drug based on BSA, the concentration of that drug in the bloodstream of one patient may be 10 times higher or lower compared to that of the other patient. This variability is typical with many chemotherapy drugs dosed by BSA, and, as shown below, was demonstrated in a study of 14 common chemotherapy drugs.
The result of this pharmacokinetic variability among patients is that many patients do not receive the right dose to achieve optimal treatment effectiveness with minimized toxic side effects. Some patients are overdosed while others are underdosed. For example, in a randomized clinical trial, investigators found 85% of metastatic colorectal cancer patients treated with 5-fluorouracil (5-FU) did not receive the optimal therapeutic dose when dosed by the BSA standard—68% were underdosed and 17% were overdosed.
There has been recent controversy over the use of BSA to calculate chemotherapy doses for obese patients. Because of their higher BSA, clinicians often arbitrarily reduce the dose prescribed by the BSA formula for fear of overdosing. In many cases, this can result in sub-optimal treatment.
Several clinical studies have demonstrated that when chemotherapy dosing is individualized to achieve optimal systemic drug exposure, treatment outcomes are improved and toxic side effects are reduced. In the 5-FU clinical study cited above, patients whose dose was adjusted to achieve a pre-determined target exposure realized an 84% improvement in treatment response rate and a six-month improvement in overall survival (OS) compared with those dosed by BSA.
In the same study, investigators compared the incidence of common 5-FU-associated grade 3/4 toxicities between the dose-adjusted patients and the BSA-dosed patients. The incidence of debilitating grades of diarrhea was reduced from 18% in the BSA-dosed group to 4% in the dose-adjusted group of patients and serious hematologic side effects were eliminated. Because of the reduced toxicity, dose-adjusted patients were able to be treated for longer periods of time. BSA-dosed patients were treated for a total of 680 months while dose-adjusted patients were treated for a total of 791 months. Completing the course of treatment is an important factor in achieving better treatment outcomes.
Similar results were found in a study involving colorectal cancer patients treated with the popular FOLFOX regimen. The incidence of serious diarrhea was reduced from 12% in the BSA-dosed group of patients to 1.7% in the dose-adjusted group, and the incidence of severe mucositis was reduced from 15% to 0.8%.
The FOLFOX study also demonstrated an improvement in treatment outcomes. Positive response increased from 46% in the BSA-dosed patients to 70% in the dose-adjusted group. Median progression free survival (PFS) and overall survival (OS) both improved by six months in the dose adjusted group.
One approach that can help clinicians individualize chemotherapy dosing is to measure the drug levels in blood plasma over time and adjust dose according to a formula or algorithm to achieve optimal exposure. With an established target exposure for optimized treatment effectiveness with minimized toxicities, dosing can be personalized to achieve target exposure and optimal results for each patient. Such an algorithm was used in the clinical trials cited above and resulted in significantly improved treatment outcomes.
Oncologists are already individualizing dosing of some cancer drugs based on exposure. Carboplatin and busulfan dosing rely upon results from blood tests to calculate the optimal dose for each patient. Simple blood tests are also available for dose optimization of methotrexate, 5-FU, paclitaxel, and docetaxel.
There are many intravenous methods of drug delivery, known as vascular access devices. These include the winged infusion device, peripheral cannula, midline catheter, peripherally inserted central catheter (PICC), central venous catheter and implantable port. The devices have different applications regarding duration of chemotherapy treatment, method of delivery and types of chemotherapeutic agent.
Depending on the patient, the cancer, the stage of cancer, the type of chemotherapy, and the dosage, intravenous chemotherapy may be given on either an inpatient or an outpatient basis. For continuous, frequent or prolonged intravenous chemotherapy administration, various systems may be surgically inserted into the vasculature to maintain access. Commonly used systems are the Hickman line, the Port-a-Cath, and the PICC line. These have a lower infection risk, are much less prone to phlebitis or extravasation, and eliminate the need for repeated insertion of peripheral cannulae.
Isolated limb perfusion (often used in melanoma), or isolated infusion of chemotherapy into the liver or the lung have been used to treat some tumors. The main purpose of these approaches is to deliver a very high dose of chemotherapy to tumor sites without causing overwhelming systemic damage. These approaches can help control solitary or limited metastases, but they are by definition not systemic, and, therefore, do not treat distributed metastases or micrometastases.
Chemotherapeutic techniques have a range of side-effects that depend on the type of medications used. The most common medications affect mainly the fast-dividing cells of the body, such as blood cells and the cells lining the mouth, stomach, and intestines. Chemotherapy-related toxicities can occur acutely after administration, within hours or days, or chronically, from weeks to years.
Immunosuppression and myelosuppression
Virtually all chemotherapeutic regimens can cause depression of the immune system, often by paralysing the bone marrow and leading to a decrease of white blood cells, red blood cells, and platelets. Anemia and thrombocytopenia, when they occur, are improved with blood transfusion. Neutropenia (a decrease of the neutrophil granulocyte count below 0.5 x 109/litre) can be improved with synthetic G-CSF (granulocyte-colony-stimulating factor, e.g., filgrastim, lenograstim).
In very severe myelosuppression, which occurs in some regimens, almost all the bone marrow stem cells (cells that produce white and red blood cells) are destroyed, meaning allogenic or autologous bone marrow cell transplants are necessary. (In autologous BMTs, cells are removed from the patient before the treatment, multiplied and then re-injected afterward; in allogenic BMTs, the source is a donor.) However, some patients still develop diseases because of this interference with bone marrow.
Although patients are encouraged to wash their hands, avoid sick people, and take other infection-reducing steps, about 85% of infections are due to naturally occurring microorganisms in the patient's own gastrointestinal tract (including oral cavity) and skin. This may manifest as systemic infections, such as sepsis, or as localized outbreaks, such as Herpes simplex, shingles, or other members of the Herpesviridea. Sometimes, chemotherapy treatments are postponed because the immune system is suppressed to a critically low level.
Due to immune system suppression, typhlitis is a "life-threatening gastrointestinal complication of chemotherapy." Typhlitis is an intestinal infection which may manifest itself through symptoms including nausea, vomiting, diarrhea, a distended abdomen, fever, chills, or abdominal pain and tenderness.
Typhlitis is a medical emergency. It has a very poor prognosis and is often fatal unless promptly recognized and aggressively treated. Successful treatment hinges on early diagnosis provided by a high index of suspicion and the use of CT scanning, nonoperative treatment for uncomplicated cases, and sometimes elective right hemicolectomy to prevent recurrence.
Nausea, vomiting, anorexia, diarrhoea, abdominal cramps, and constipation are common side-effects of chemotherapeutic medications that kill fast-dividing cells. Malnutrition and dehydration can result when the patient does not eat or drink enough, or when the patient vomits frequently, because of gastrointestinal damage. This can result in rapid weight loss, or occasionally in weight gain, if the patient eats too much in an effort to allay nausea or heartburn. Weight gain can also be caused by some steroid medications. These side-effects can frequently be reduced or eliminated with antiemetic drugs. Self-care measures, such as eating frequent small meals and drinking clear liquids or ginger tea, are often recommended. In general, this is a temporary effect, and frequently resolves within a week of finishing treatment. However, a high index of suspicion is appropriate, since diarrhea and bloating are also symptoms of typhlitis, a very serious and potentially life-threatening medical emergency that requires immediate treatment.
Anemia in cancer patients can be a combined outcome caused by myelosuppressive chemotherapy, and possible cancer-related causes such as bleeding, blood cell destruction (hemolysis), hereditary disease, kidney dysfunction, nutritional deficiencies and/or anemia of chronic disease. Treatments to mitigate anemia include hormones to boost blood production (erythropoietin), iron supplements, and blood transfusions. Myelosuppressive therapy can cause a tendency to bleed easily, leading to anemia. Medications that kill rapidly dividing cells or blood cells can reduce the number of platelets in the blood, which can result in bruises and bleeding. Extremely low platelet counts may be temporarily boosted through platelet transfusions and new drugs to increase platelet counts during chemotherapy are being developed. Sometimes, chemotherapy treatments are postponed to allow platelet counts to recover.
Fatigue may be a consequence of the cancer or its treatment, and can last for months to years after treatment. One physiological cause of fatigue is anemia, which can be caused by chemotherapy, surgery, radiotherapy, primary and metastatic disease and/or nutritional depletion. Anaerobic exercise has been found to be beneficial in reducing fatigue in people with solid tumours.
Nausea and vomiting
Nausea and vomiting are two of the most feared cancer treatment-related side-effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side-effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. Chemotherapy-induced nausea and vomiting (CINV) are common with many treatments and some forms of cancer. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to successfully manage these symptoms in a large portion of patients. Effective mediation of these unpleasant and sometimes-crippling symptoms results in increased quality of life for the patient and more efficient treatment cycles, due to less stoppage of treatment due to better tolerance by the patient, and due to better overall health of the patient.
Hair loss (Alopecia) can be caused by chemotherapy that kills rapidly dividing cells; other medications may cause hair to thin. These are most often temporary effects: hair usually starts to regrow a few weeks after the last treatment, and can sometimes change colour, texture, thickness and style. Sometimes hair has a tendency to curl after regrowth, resulting in "chemo curls." Severe hair loss occurs most often with drugs such as doxorubicin, daunorubicin, paclitaxel, docetaxel, cyclophosphamide, ifosfamide and etoposide. Permanent thinning or hair loss can result from some standard chemotherapy regimens.
Chemotherapy induced hair loss occurs by a non-androgenic mechanism, and can manifests as alopecia totalis, telogen effluvium, or less often alopecia areata. It is usually associated with systemic treatment due to the high mitotic rate of hair follicles, and more reversible than androgenic hair loss, although permanent cases can occur. Chemotherapy induces hair loss in women more often than men.
Development of secondary neoplasia after successful chemotherapy and/or radiotherapy treatment can occur. The most common secondary neoplasm is secondary acute myeloid leukemia, which develops primarily after treatment with alkylating agents or topoisomerase inhibitors. Survivors of childhood cancer are more than 13 times as likely to get a secondary neoplasm during the 30 years after treatment than the general population. Not all of this increase can be attributed to chemotherapy.
Some types of chemotherapy are gonadotoxic and may cause infertility. Chemotherapies with high risk include procarbazine and other alkylating drugs such as cyclophosphamide, ifosfamide, busulfan, melphalan, chlorambucil, and chlormethine. Drugs with medium risk include doxorubicin and platinum analogs such as cisplatin and carboplatin. On the other hand, therapies with low risk of gonadotoxicity include plant derivatives such as vincristine and vinblastine, antibiotics such as bleomycin and dactinomycin, and antimetabolites such as methotrexate, mercaptopurine, and 5-fluorouracil.
Female infertility by chemotherapy appears to be secondary to premature ovarian failure by loss of primordial follicles. This loss is not necessarily a direct effect of the chemotherapeutic agents, but could be due to an increased rate of growth initiation to replace damaged developing follicles.
Patients may choose between several methods of fertility preservation prior to chemotherapy, including cryopreservation of semen, ovarian tissue, oocytes, or embryos. As more than half of cancer patients are elderly, this adverse effect is only relevant for a minority of patients. A study in France between 1999 and 2011 came to the result that embryo freezing before administration of gonadotoxic agents to females caused a delay of treatment in 34% of cases, and a live birth in 27% of surviving cases who wanted to become pregnant, with the follow-up time varying between 1 and 13 years.
Potential protective or attenuating agents include GnRH analogs, where several studies have shown a protective effect in vivo in humans, but some studies show no such effect. Sphingosine-1-phosphate (S1P) has shown similar effect, but its mechanism of inhibiting the sphingomyelin apoptotic pathway may also interfere with the apoptosis action of chemotherapy drugs.
In chemotherapy as a conditioning regimen in hematopoietic stem cell transplantation, a study of patients conditioned with cyclophosphamide alone for severe aplastic anemia came to the result that ovarian recovery occurred in all women younger than 26 years at time of transplantation, but only in five of 16 women older than 26 years.
Chemotherapy is potentially teratogenic during pregnancy, especially during the first trimester, to the extent that abortion usually is recommended if pregnancy in this period is found during chemotherapy. Second- and third-trimester exposure does not usually increase the teratogenic risk and adverse effects on cognitive development, but it may increase the risk of various complications of pregnancy and fetal myelosuppression.
In males previously having undergone chemotherapy or radiotherapy, there appears to be no increase in genetic defects or congenital malformations in their children conceived after therapy. The use of assisted reproductive technologies and micromanipulation techniques might increase this risk. In females previously having undergone chemotherapy, miscarriage and congenital malformations are not increased in subsequent conceptions. However, when in vitro fertilization and embryo cryopreservationis practised between or shortly after treatment, possible genetic risks to the growing oocytes exist, and hence it has been recommended that the babies be screened.
Between 30 and 40 percent of patients undergoing chemotherapy experience chemotherapy-induced peripheral neuropathy (CIPN), a progressive, enduring, and often irreversible condition, causing pain, tingling, numbness and sensitivity to cold, beginning in the hands and feet and sometimes progressing to the arms and legs. Chemotherapy drugs associated with CIPN include thalidomide, epothilones, vinca alkaloids, taxanes, proteasome inhibitors, and the platinum-based drugs. Whether CIPN arises, and to what degree, is determined by the choice of drug, duration of use, the total amount consumed and whether the patient already has peripheral neuropathy. Though the symptoms are mainly sensory, in some cases motor nerves and the autonomic nervous system are affected. CIPN often follows the first chemotherapy dose and increases in severity as treatment continues, but this progression usually levels off at completion of treatment. The platinum-based drugs are the exception; with these drugs, sensation may continue to deteriorate for several months after the end of treatment. Some CIPN appears to be irreversible. Pain can often be managed with drug or other treatment but the numbness is usually resistant to treatment.
Some patients report fatigue or non-specific neurocognitive problems, such as an inability to concentrate; this is sometimes called post-chemotherapy cognitive impairment, referred to as "chemo brain" by patients' groups.
Tumor lysis syndrome
In particularly large tumors and cancers with high white cell counts, such as lymphomas, teratomas, and some leukemias, some patients develop tumor lysis syndrome. The rapid breakdown of cancer cells causes the release of chemicals from the inside of the cells. Following this, high levels of uric acid, potassium and phosphate are found in the blood. High levels of phosphate induce secondary hypoparathyroidism, resulting in low levels of calcium in the blood. This causes kidney damage and the high levels of potassium can cause cardiac arrhythmia. Although prophylaxis is available and is often initiated in patients with large tumors, this is a dangerous side-effect that can lead to death if left untreated.
Cardiotoxicity (heart damage) is especially prominent with the use of anthracycline drugs (doxorubicin, epirubicin, idarubicin, and liposomal doxorubicin). The cause of this is most likely due to the production of free radicals in the cell and subsequent DNA damage. Other chemotherapeutic agents that cause cardiotoxicity, but at a lower incidence, are cyclophosphamide, docetaxel and clofarabine.
Hepatotoxicity (liver damage) can be caused by many cytotoxic drugs. The susceptibility of an individual to liver damage can be altered by other factors such as the cancer itself, viral hepatitis, immunosuppression and nutritional deficiency. The liver damage can consist of damage to liver cells, hepatic sinusoidal syndrome (obstruction of the veins in the liver), cholestasis (where bile does not flow from the liver to the intestine) and liver fibrosis.
Nephrotoxicity (kidney damage) can be caused by tumor lysis syndrome and also due direct effects of drug clearance by the kidneys. Different drugs will affect different parts of the kidney and the toxicity may be asymptomatic (only seen on blood or urine tests) or may cause acute renal failure.
Less common side-effects include red skin (erythema), dry skin, damaged fingernails, a dry mouth (xerostomia), water retention, and sexual impotence. Some medications can trigger allergic or pseudoallergic reactions.
Specific chemotherapeutic agents are associated with organ-specific toxicities, including cardiovascular disease(e.g., doxorubicin), interstitial lung disease (e.g., bleomycin) and occasionally secondary neoplasm (e.g., MOPP therapy for Hodgkin's disease).
Chemotherapy does not always work, and even when it is useful, it may not completely destroy the cancer. Patients frequently fail to understand its limitations. In one study of patients who had been newly diagnosed with incurable, stage 4 cancer, more than two-thirds of patients with lung cancer and more than four-fifths of patients with colorectal cancer still believed that chemotherapy was likely to cure their cancer.
The blood–brain barrier poses a difficult obstacle to pass to deliver chemotherapy to the brain. This is because the brain has an extensive system in place to protect it from harmful chemicals. Drug transporters can pump out drugs from the brain and brain's blood vessel cells into the cerebrospinal fluid and blood circulation. These transporters pump out most chemotherapy drugs, which reduces their efficacy for treatment of brain tumors. Only small lipophilic alkylating agents such as lomustine or temozolomide are able to cross this blood–brain barrier.
Blood vessels in tumors are very different from those seen in normal tissues. As a tumor grows, tumor cells furthest away from the blood vessels become low in oxygen (hypoxic). To counteract this they then signal for new blood vessels to grow. The newly formed tumor vasculature is poorly formed and does not deliver an adequate blood supply to all areas of the tumor. This leads to issues with drug delivery because many drugs will be delivered to the tumor by the circulatory system.
The efficacy of chemotherapy depends on the type of cancer and the stage. The overall effectiveness ranges from being curative for some cancers, such as some leukemias, to being ineffective, such as in some brain tumors, to being needless in others, like most non-melanoma skin cancers.
An investigation by the Department of Radiation Oncology, Northern Sydney Cancer Centre, Australia, into the contribution of chemotherapy to 5-year survival in 22 major adult malignancies, showed startling results: The overall contribution of curative and adjuvant cytotoxic chemotherapy to 5-year survival in adults was estimated to be 2.3% in Australia and 2.1% in the USA. The study published in 2004 came to the following conclusion: "..it is clear that cytotoxic chemotherapy only makes a minor contribution to cancer survival. To justify the continued funding and availability of drugs used in cytotoxic chemotherapy, a rigorous evaluation of the cost-effectiveness and impact on quality of life is urgently required." 
Resistance is a major cause of treatment failure in chemotherapeutic drugs. There are a few possible causes of resistance in cancer, one of which is the presence of small pumps on the surface of cancer cells that actively move chemotherapy from inside the cell to the outside. Cancer cells produce high amounts of these pumps, known as p-glycoprotein, in order to protect themselves from chemotherapeutics. Research on p-glycoprotein and other such chemotherapy efflux pumps is currently ongoing. Medications to inhibit the function of p-glycoprotein are undergoing investigation, but due to toxicities and interactions with anti-cancer drugs their development has been difficult. Another mechanism of resistance is gene amplification, a process in which multiple copies of a gene are produced by cancer cells. This overcomes the effect of drugs that reduce the expression of genes involved in replication. With more copies of the gene, the drug can not prevent all expression of the gene and therefore the cell can restore its proliferative ability. Cancer cells can also cause defects in the cellular pathways of apoptosis (programmed cell death). As most chemotherapy drugs kill cancer cells in this manner, defective apoptosis allows survival of these cells, making them resistant. Many chemotherapy drugs also cause DNA damage, which can be repaired by enzymes in the cell that carry out DNA repair. Upregulation of these genes can overcome the DNA damage and prevent the induction of apoptosis. Mutations in genes that produce drug target proteins, such as tubulin, can occur which prevent the drugs from binding to the protein, leading to resistance to these types of drugs.
Cytotoxics and targeted therapies
Targeted therapies are a relatively new class of cancer drugs that can overcome many of the issues seen with the use of cytotoxics. They are divided into two groups: small molecule and antibodies. The massive toxicity seen with the use of cytotoxics is due to the lack of cell specificity of the drugs. They will kill any rapidly dividing cell, tumor or normal. Targeted therapies are designed to affect cellular proteins or processes that are utilised by the cancer cells. This allows a high dose to cancer tissues with a relatively low dose to other tissues. As different proteins are utilised by different cancer types, the targeted therapy drugs are used on a cancer type specific, or even on a patient specific basis. Although the side effects are often less severe than that seen of cytotoxic chemotherapeutics, life-threatening effects can occur. Initially, the targeted therapeutics were supposed to be solely selective for one protein. Now it is clear that there is often a range of protein targets that the drug can bind. An example target for targeted therapy is the protein produced by the Philadelphia chromosome, a genetic lesion found commonly in chronic myelomonocytic leukemia. This fusion protein has enzyme activity that can be inhibited by imatinib, a small molecule drug.
Newer and experimental approaches
Specially targeted delivery vehicles aim to increase effective levels of chemotherapy for tumor cells while reducing effective levels for other cells. This should result in an increased tumor kill and/or reduced toxicity.
Antibody-drug conjugates (ADCs) comprise an antibody, drug and a linker between them. The antibody will be targeted at a preferentially expressed protein in the tumour cells (known as a tumor antigen) or on cells that the tumor can utilise, such as blood vessel endothelial cells. They bind to the tumor antigen and are internalised, where the linker releases the drug into the cell. These specially targeted delivery vehicles vary in their stability, selectivity, and choice of target, but, in essence, they all aim to increase the maximum effective dose that can be delivered to the tumor cells. Reduced systemic toxicity means that they can also be used in sicker patients, and that they can carry new chemotherapeutic agents that would have been far too toxic to deliver via traditional systemic approaches.
The first approved drug of this type was gemtuzumab ozogamicin (Mylotarg), released by Wyeth (now Pfizer). The drug was approved to treat acute myeloid leukemia, but has now been withdrawn from the market because the drug did not meet efficacy targets in further clinical trials. Two other drugs, trastuzumab emtansine and brentuximab vedotin, are both in late clinical trials, and the latter has been granted accelerated approval for the treatment of refractory Hodgkins lymphoma and systemic anaplastic large cell lymphoma.
Nanoparticles are 1-1000 nanometer (nm) sized particles that can promote tumor selectivity and aid in delivering low-solubility drugs. Nanoparticles can be targeted passively or actively. Passive targeting exploits the difference between tumor blood vessels and normal blood vessels. Blood vessels in tumors are "leaky" because they have gaps from 200-2000 nm, which allow nanoparticles to escape into the tumor. Active targeting uses biological molecules (antibodies, proteins, DNA and receptor ligands) to preferentially target the nanoparticles to the tumor cells. There are many types of nanoparticle delivery systems, such as silica, polymers, liposomes and magnetic particles. Nanoparticles made of magnetic material can also be used to concentrate agents at tumor sites using an externally applied magnetic field. They have emerged as a useful vehicle for poorly soluble agents such as paclitaxel.
Electrochemotherapy is the combined treatment in which injection of a chemotherapeutic drug is followed by application of high-voltage electric pulses locally to the tumor. The treatment enables the chemotherapeutic drugs, which otherwise cannot or hardly go through the membrane of cells (such as bleomycin and cisplatin), to enter the cancer cells. Hence, greater effectiveness of antitumor treatment is achieved.
Clinical electrochemotherapy has been successfully used for treatment of cutaneous and subcutaneous tumors irrespective of their histological origin. The method has been reported as safe, simple and highly effective in all reports on clinical use of electrochemotherapy. According to the ESOPE project (European Standard Operating Procedures of Electrochemotherapy), the Standard Operating Procedures (SOP) for electrochemotherapy were prepared, based on the experience of the leading European cancer centres on electrochemotherapy. Recently, new electrochemotherapy modalities have been developed for treatment of internal tumors using surgical procedures, endoscopic routes or percutaneous approaches to gain access to the treatment area.
Hyperthermia therapy is heat treatment for cancer that can be a powerful tool when used in combination with chemotherapy (thermochemotherapy) or radiation for the control of a variety of cancers. The heat can be applied locally to the tumor site, which will dilate blood vessels to the tumor, allowing more chemotherapeutic medication to enter the tumor. Additionally, the bi-lipid layer of the tumor cell membrane will become more porous, further allowing more of the chemotherapeutic medicine to enter the tumor cell.
Hyperthermia has also been shown to help prevent or reverse "chemo-resistance." Chemotherapy resistance sometimes develops over time as the tumors adapt and can overcome the toxicity of the chemo medication. "Overcoming chemoresistance has been extensively studied within the past, especially using CDDP-resistant cells. In regard to the potential benefit that drug-resistant cells can be recruited for effective therapy by combining chemotherapy with hyperthermia, it was important to show that chemoresistance against several anticancer drugs (e.g. mitomycin C, anthracyclines, BCNU, melphalan) including CDDP could be reversed at least partially by the addition of heat.
Some chemotherapy drugs are used in diseases other than cancer, such as in autoimmune disorders, and noncancerous plasma cell dyscrasia. In some cases they are often used at lower doses, which means that the side effects are minimized. Methotrexate is used in the treatment of rheumatoid arthritis (RA), psoriasis, ankylosing spondylitis and multiple sclerosis. The anti-inflammatory response seen in RA is thought to be due to increases in adenosine, which causes immunosuppression; effects on immuno-regulatory cyclooxygenase-2 enzyme pathways; reduction in pro-inflammatory cytokines; and anti-proliferative properties. Although methotrexate is used to treat both multiple sclerosis and ankylosing spondylitis, its efficacy in these diseases is still uncertain. Cyclophosphamide is sometimes used to treat lupus nephritis, a common symptom of systemic lupus erythematosus. Dexamethasone along with either bortezomib or melphalan is commonly used as a treatment for AL amyloidosis. Recently, bortezomid in combination with cyclophosphamide and dexamethasone has also shown promise as a treatment for AL amyloidosis. Other drugs used to treat myeloma such as lenalidomide have shown promise in treating AL amyloidosis.
Chemotherapy drugs are also used in conditioning regimens prior to bone marow transplant (hematopoietic stem cell transplant). Conditioning regimens are used to suppress the recipient's immune system in order to allow a transplant to engraft. Cyclophosphamide is a common cytotoxic drug used in this manner, and is often used in conjunction with total body irradiation. Chemotherapeutic drugs may be used at high doses to permanently remove the recipient's bone marrow cells (myeloablative conditioning) or at lower doses that will prevent permanent bone marrow loss (non-myeloablative and reduced intensity conditioning).
Healthcare workers exposed to antineoplastic agents take precautions to keep their exposure to a minimum. There is a limitation in cytotoxics dissolution in Australia and the United States to 20 dissolutions per pharmacist/nurse, since pharmacists who prepare these drugs or nurses who may prepare or administer them are the two occupational groups with the highest potential exposure to antineoplastic agents. In addition, physicians and operating room personnel may also be exposed through the treatment of patients. Hospital staff, such as shipping and receiving personnel, custodial workers, laundry workers, and waste handlers, all have potential exposure to these drugs during the course of their work. The increased use of antineoplastic agents in veterinary oncology also puts these workers at risk for exposure to these drugs. Routes of entry into the worker's body are skin absorption, inhalation, and ingestion via hand-to-mouth. The long-term effects of exposure include chromosomal abnormalities and infertility.
In other animals
Chemotherapy is used in veterinary medicine similar to how it is used in human medicine.
Comparison of available agents
|INN||Reviews||Chemical classification||Preg. cat.||Route||Mechanism of action||Indications||Major toxicities|
|1. Cytotoxic antineoplastics|
|1.01 Nucleoside analogues|
|Cytidine analogue||X (Au)||SC, IV||DNA methyltransferase inhibitor and incorporates itself into RNA, hence inhibiting gene expression.||Myelodysplastic syndromes, acute myeloid leukaemia and chronic myeloid leukaemia||Myelosuppression, kidney failure (uncommon/rare), renal tubular acidosis and hypokalaemia.|
|Uracil analogue||D (Au)||PO||Fluorouracilprodrug||Breast, colorectal, gastric and oesophageal cancer||Myelosuppression, cardiotoxicity, hypertriglyceridaemia, GI haemorrhage (uncommon), cerebellar syndrome (uncommon), encephalopathy (uncommon) and diarrhoea.|
|Carmofur||N/A||Uracil analogue||N/A||PO||Fluorouracil prodrug||Colorectal, breast and ovarian cancer||Myelosuppression, neurotoxicity and diarrhoea.|
|Adenosine analogue||D (Au)||PO, SC, IV||DNA methyltransferaseinhibitor, metabolites incorporate themselves into DNA.||Hairy cell leukaemia, chronic lymphocytic leukaemia, Waldenstrom macroglobulinaemia and multiple sclerosis.||Myelosuppression, haemolytic anaemia (uncommon), neurotoxicity (rare), renal impairment (rare), pulmonary interstitial infiltrates (rare), Stevens-Johnson syndrome (rare) and toxic epidermal necrolysis (rare).|
|Deoxyadenosineanalogue||D (Au)||IV||Ribonucleotide reductase and DNA polymerase inhibitor.||Acute lymphoblastic leukaemia and acute myeloid leukaemia||Myelosuppression, hypokalaemia, cytokine release syndrome, Stevens-Johnson syndrome(uncommon), toxic epidermal necrolysis (uncommon) and pancreatitis (uncommon)|
|Cytarabine||||Cytidine analogue||D (Au)||SC, IM, IV, IT||DNA polymerase inhibitor, S-phase specific. Incorporates its metabolites into DNA.||Acute myeloid leukaemia, acute lymphoblastic leukaemia, chronic myeloid leukaemia, lymphomas, progressive multifocal leucoencephalopathy and meningeal leukaemia||Myelosuppression, GI bleeds, pancreatitis (uncommon/rare), anaphylaxis (uncommon/rare), pericarditis (uncommon/rare) and conjunctivitis (uncommon/rare). High dose: cerebral and cerebellar dysfunction, ocular toxicity, pulmonary toxicity, severe GI ulceration and peripheral neuropathy (rare).|
|Cytidine analogue.||D (US)||IV||DNA methyltransferase inhibitor.||Myelodysplastic syndrome, sickle cell anaemia (orphan), acute myeloid leukaemia and chronic myeloid leukaemia.||Myelosuppression, hyperglycaemia, hypoalbuminaemia, hypomagnesaemia, hypokalaemia, hyperkalaemia and thrombocythaemia.|
|Floxuridine||||Uracil analogue||D (US)||IA||Fluorouracil analogue.||Metastatic GI adenocarcinoma and stomach cancer||Myelosuppression.|
|Adenosine analogue||D (Au)||PO, IV||DNA polymerase and ribonucleotide reductase inhibitor.||Acute myeloid leukaemia, chronic lymphocytic leukaemia, non-Hodgkin lymphoma and Waldenstrom macroglobulinaemia.||Myelosuppression, hyperglycaemia, GI bleeds (uncommon), pneumonitis (uncommon), haemolytic anaemia (uncommon), severe neurotoxicity (rare), haemorrhagic cystitis (rare), Stevens-Johnson syndrome (rare) and Toxic Epidermal Necrolysis (rare).|
|Fluorouracil||||Uracil analogue||D (Au)||IV||Thymidylate synthase inhibitor.||Anal, breast, colorectal, gastric, head and neck, oesophageal and pancreatic cancer. Bowen's disease and actinic keratoses.||Myelosuppression, diarrhoea, cardiotoxicity, GI ulceration and bleeding (uncommon), cerebellar syndrome (uncommon), encephalopathy (uncommon) and anaphylaxis (rare).|
|Deoxycytidine analogue||D (Au)||IV||DNA synthesis inhibitor, induces apoptosis specifically in S-phase.||Bladder, breast, nasopharyngeal, non-small cell lung, ovarian and pancreatic cancer, lymphomas and inflammatory bowel disease.||Myelosuppression, pulmonary toxicity, kidney failure (rare), haemolytic uraemic syndrome(rare), thrombotic thrombocytopenic purpura (rare), anaphylactoid reaction (rare), reversible posterior leucoencephalopathy syndrome (rare), myocardial infarction (rare) and heart failure (rare).|
|Mercaptopurine||||Hypoxanthine analogue||D (Au)||PO||Purine synthesis inhibitor.||Acute lymphoblastic leukaemia, acute promyelocytic leukaemia, lymphoblastic lymphoma and inflammatory bowel disease.||Myelosuppression, hepatotoxicity, GI ulceration (rare), pancreatitis (rare) and secondary leukaemia (rare) or myelodysplasia (rare).|
|Adenosine analogue||D (US)||IV||Purine synthesis inhibitor.||Acute lymphoblastic leukaemia and chronic lymphocytic leukaemia.||Myelosuppression, pleural effusion, seizures, tumour lysis syndrome and a condition similar to Guillain-Barré syndrome.|
|Adenosine analogue||D (US)||IV||Adenosine deaminase inhibitor.||Hairy cell leukaemia, peripheral T-cell lymphoma (orphan), cutaneous T cell lymphoma (orphan) and chronic lymphocytic leukaemia (orphan).||Myelosuppression, neurotoxicity, immune hypersensitivity, hyponatraemia, thrombotic thrombocytopenic purpura and microangiopathic hemolytic anaemia.|
|Fluorouracilanalogue||D (Au)||PO||Thymidylate synthase inhibitor.||Breast, colorectal cancer, gallbladder, gastrointestinal tract, head and neck, liver and pancreas cancer.||Myelosuppression, diarrhoea, neurotoxicity and hepatitis (rare).|
|Guanine analogue.||D (Au)||PO||Purine synthesis inhibitor.||Acute lymphoblastic leukaemia and acute myeloid leukaemia||Myelosuppression, hepatotoxicity, peripheral neuropathy (uncommon), intestinal necrosis (rare) and perforation (rare).|
|Folate analogue||D (Au)||SC, IM, IV, IT, PO||Dihydrofolate reductase inhibitor.||Bladder and breast cancer. squamous cell carcinoma of head and neck, gestational trophoblastic disease, acute leukaemias, non-Hodgkin lymphoma, osteosarcoma, brain tumours, graft-versus-host disease and systemic sclerosis.||Myelosuppression, pulmonary toxicity, hepatotoxicity, neurotoxicity (high dose or intrathecal administration), anaphylactic reactions (rare), Stevens-Johnson syndrome (rare), Toxic Epidermal Necrolysis (rare), kidney failure (rare), osteoporosis (rare), skin and bone necrosis (rare) and macrocytic anaemia (rare).|
|Folate analogue||D (Au)||IV||Dihydrofolate reductase, thymidylate synthase and glycinamide ribonucleotide formyltransferase inhibitors.||Malignant mesothelioma and non-squamous non-small cell lung cancer.||Myelosuppression, renal impairment, peripheral neuropathy, Supraventricular tachycardia (uncommon), hepatitis (rare), colitis (rare), pneumonitis (rare), radiation recall (rare), Stevens-Johnson syndrome (rare) and toxic epidermal necrolysis (rare).|
|Quinazolinone||D (Au)||IV||Dihydrofolate reductase and thymidylate synthase inhibitor.||Colorectal cancer||Myelosuppression|
|1.03 Other antimetabolites|
|Urea analogue||D (Au)||PO||Inhibits DNA synthesis by inhibiting the enzyme ribonucleotide reductase.||Chronic myeloid leukaemia, essential thrombocytosis, polycythaemia vera, myelofibrosis, acute myeloid leukaemia and sickle cell anaemia||Myelosuppression, skin cancer (rare), oedema (rare), hallucinations (rare), seizures (rare) and pulmonary toxicity (rare).|
|1.04 Topoisomerase I inhibitor|
|Irinotecan||Camptothecin||D (Au)||IV||Inhibits topoisomerase I.||Colorectal cancer||Diarrhoea, myelosuppression, pulmonary infiltrates (uncommon), bradycardia (uncommon), ileus (rare) and colitis (rare).|
|Topotecan||Camptothecin||D (Au)||IV||Inhibits topoisomerase I.||Small cell lung cancer, ovarian cancer and cervical cancer||Diarrhoea, myelosuppression, interstitial lung disease and allergy.|
|Daunorubicin||Anthracycline||D (Au)||IV||Inhibits DNA and RNA synthesis by intercalating DNA base pairs. Inhibits DNA repair by inhibiting topoisomerase II.||Acute leukaemias||Myelosuppression, cardiotoxicity, anaphylaxis (rare), secondary malignancies (particularly acute myeloid leukaemia and myelodysplastic syndrome) and radiation recall.|
|Doxorubicin||Anthracycline||D (Au)||IV||As above.||Breast cancer, lymphomas, sarcomas, bladder cancer, acute lymphoblastic leukaemia, Wilms' tumour, AIDS-related Kaposi's sarcoma, neuroblastoma and multiple myeloma||As above.|
|Epirubicin||Anthracycline||D (Au)||IV||As above.||Breast cancer, gastric cancer and bladder cancer||As above.|
|Idarubicin||Anthracycline||D (Au)||IV, PO||As above.||Acute leukaemias.||As above.|
|Mitoxantrone||Anthracenedione||D (Au)||IV||As above.||Non-Hodgkin lymphoma, acute myeloid leukaemia, prostate cancer and multiple sclerosis||As above.|
|Valrubicin||Anthracycline||C (US)||IV||As above.||Bladder cancer.||As above.|
|Etoposide||Podophyllotoxin||D (Au)||IV, PO||Topoisomerase II inhibitor.||Testicular cancer, ovarian cancer, lung cancer, acute myeloid leukaemia, lymphomas and sarcomas||Myelosuppression, hypersensitivity reactions, Stevens-Johnson syndrome (rare), peripheral neuropathy (uncommon) and secondary malignancies (especially acute myeloid leukaemia).|
|Teniposide||Podophyllotoxin||D (Au)||IV||Topoisomerase II inhibitor.||Lymphomas, acute lymphoblastic leukaemia and neuroblastoma||As above.|
|Cabazitaxel||Taxane||D (Au)||IV||Microtubule disassembly inhibitor. Arrests cells in late G2 phase and M phase.||Prostate cancer||Myelosuppression, diarrhoea, kidney failure, hypersensitivity, severe GI reactions (including perforation, ileus, colitis, etc.; all rare) and peripheral neuropathy|
|Docetaxel||Taxane||D (Au)||IV||As above.||Breast cancer, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell head and neck cancer and gastric cancer.||Myelosuppression, peripheral neuropathy, hypersensitivity, fluid retention, heart failure (uncommon), pulmonary toxicity (rare), radiation recall (rare), scleroderma-like skin changes (rare), Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare), seizures (rare) and encephalopathy (rare)|
|Paclitaxel||Taxane||D (Au)||IV||As above.||Ovarian cancer, breast cancer, non-small cell lung cancer, AIDS-related Kaposi's sarcoma, cervical cancer, germ cell cancer and endometrial cancer||Hypersensitivity, myelosuppression, peripheral neuropathy, myocardial infarction (uncommon), arrhythmias (uncommon), pulmonary toxicity (rare), radiation recall (rare), scleroderma-like skin changes (rare), Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare), seizures (rare) and encephalopathy (rare).|
|1.08 Vinca alkaloids|
|Vinblastine||Vinca alkaloid||D (Au)||IV||Microtubule assembly inhibitor. Arrests cells in M phase.||Hodgkin lymphoma, germ cell tumours, non-small cell lung cancer, bladder cancer and primary immune thrombocytopenia||Neurotoxicity, myelosuppression, myocardial ischaemia (rare) and myocardial infarction (rare).|
|Vincristine||Vinca alkaloid||D (Au)||IV||As above.||Lymphomas, acute lymphoblastic leukaemia, multiple myeloma, sarcoma, brain tumours, Wilms' tumour, neuroblastoma and primary immune thrombocytopenia||Neurotoxicity, anaphylaxis (rare), myocardial ischaemia (rare) and myocardial infarction (rare).|
|Vindesine||Vinka alkaloid||D (Au)||IV||As above.||Refractory metastatic melanoma, childhood acute lymphoblastic leukaemia, chronic myeloid leukaemia in blast crises, neuroblastoma, non-small cell lung cancer and breast cancer.||Myelosuppression, neurotoxicity and paralytic ileus.|
|Vinflunine||Vinca alkaloid||D (Au)||IV||As above.||Bladder cancer||As per vinblastine.|
|Vinorelbine||Vinca alkaloid||D (Au)||IV||As above.||Breast cancer and non-small cell lung cancer.||As above.|
|1.09 Alkylating agents|
|Bendamustine||Nitrogen mustard||D (Au)||IV||Alkylates DNA.||Chronic lymphocytic leukaemia, mantle cell lymphoma and non-Hodgkin's lymphoma.||Myelosuppression, hypokalaemia and tachycardia.|
|Busulfan||Dialkylsulfonate||D (Au)||IV, PO||Alkylates DNA.||Conditioning treatment before haematopoietic stem cell transplantation (high dose, IV), chronic myeloid leukaemia, myelofibrosis, polycythaemia vera and essential thrombocytosis||Myelosuppression, seizures (high dose), tachycardia (high dose), hepatic sinusoidal obstruction syndrome (high dose), Addison-like syndrome (rare), pulmonary fibrosis (rare), cataracts (rare) and hepatitis (rare). Secondary malignancies.|
|Carmustine||Nitrosourea||D (Au)||IV||Alkylates DNA.||Anaplastic astrocytoma, glioblastoma multiforme and mycosis fungoides (topical)||Myelosuppression, pulmonary fibrosis, pulmonary infiltrates, seizure, brain oedema, cerebrospinal leaks, subdural fluid collection, intracranial infection, hypotension (uncommon), tachycardia (uncommon), decrease in kidney size (reversible), uraemia (uncommon), kidney failure (uncommon), severe hepatic toxicity (rare), thrombosis (rare) and neuroretinitis (rare). Secondary malignancies.|
|Chlorambucil||Nitrogen mustard||D (Au)||IV||Alkylates DNA.||Lymphoma, chronic lymphocytic leukaemia and Waldenström's macroglobulinaemia||Myelosuppression, hallucinations (rare), seizures (rare), sterile cystitis (rare), hepatotoxicity (rare), severe pneumonitis (rare), Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare) and drug fever (rare). Secondary malignancies.|
|Chlormethine||Nitrogen mustard||D (Au)||IV, topical||Alkylates DNA.||Cutaneous T-Cell Lymphoma, metastatic carcinoma, leukaemias, lymphomas, polycythemia vera and bronchogenic carcinoma||Thrombosis, myelosuppression (common), hyperuricaemia, erythema multiforme, haemolytic anaemia, nausea and vomiting (severe) and secondary malignancies.|
|Cyclophosphamide||Nitrogen mustard||D (Au)||IV||Alkylates DNA.||Breast cancer, lymphoma, acute lymphoblastic leukaemia, chronic lymphocytic leukaemia, sarcoma, multiple myeloma, Waldenström's macroglobulinaemia, systemic lupus erythematosus, glomerulonephritis, systemic vasculitis and Wegener's granulomatosis||Myelosuppression, nausea and vomiting (>30%), haemorrhagic cystitis, heart failure (rare), pulmonary fibrosis (rare), hepatic sinusoidal obstruction syndrome (rare), water retention resembling SIADH (rare) and seizures (rare). Secondary malignancies.|
|Dacarbazine||Triazene||D (Au)||IV||Alkylates DNA.||Hodgkin lymphoma, metastatic malignant melanoma and soft tissue sarcoma||Myelosuppression, agranulocytosis (uncommon), hepatic vein thrombosis (rare) and hepatocellular necrosis (rare). Secondary malignancies.|
|Fotemustine||Nitrosourea||D (Au)||IV||Alkylates DNA.||Metastatic malignant melanoma.||Myelosuppression.|
|Ifosfamide||Nitrogen mustard||D (Au)||IV||Alkylates DNA.||Sarcomas, testicular cancer and lymphomas.||Myelosuppression, haemorrhagic cystitis, nephrotoxicity, neurotoxicity and cardiac toxicity (rare). Secondary malignancies.|
|Lomustine||Nitrosourea||D (Au)||PO||Alkylates DNA.||Glioma and medulloblastoma.||Myelosuppression, pulmonary infiltration and fibrosis. Secondary malignancies.|
|Melphalan||Nitrogen mustard||D (Au)||IV, PO||Alkylates DNA.||Malignant melanoma of the extremities, multiple myeloma, conditioning treatment before haemopoietic stem cell transplant.||Myelosuppression, pulmonary fibrosis and pneumonitis (uncommon), skin necrosis (uncommon), anaphylaxis, hepatic sinusoidal obstruction syndrome and SIADH. Secondary malignancies.|
|Streptozotocin||Nitrosourea||D (Au)||IV, PO||Alkylates DNA.||Pancreatic cancer and carcinoid syndrome.||Nephrotoxicity, hypoglycaemia, myelosuppression, nausea and vomiting (>90%), jaundice and nephrogenic diabetes insipidus (rare).|
|Temozolomide||Triazene||D (US)||PO||Alkylates DNA.||Anaplastic astrocytoma, glioblastoma multiforme, metastatic malignant melanoma||Myelosuppression, Stevens-Johnson syndrome (rare), pneumonitis (rare) and hepatitis (rare).|
|1.10 Platinum compounds|
|Carboplatin||Platinum complex||D (Au)||IV||Reacts with DNA, inducing apoptosis, non-cell cycle specific.||Ovarian cancer, lung cancer and squamous cell head and neck cancer||Myelosuppression, nausea and vomiting (30-90%), peripheral neuropathy, ototoxicity, anaphylaxis, acute kidney failure (rare), haemolytic uraemic syndrome (rare) and loss of vision (rare).|
|Cisplatin||Platinum complex||D (Au)||IV||As above.||Germ cell tumours (including testicular cancer), ovarian cancer, cervical cancer, small cell and non-small cell lung cancer, mesothelioma, squamous cell head and neck cancer, oesophageal cancer, gastric cancer, bladder cancer and osteosarcoma||Nephrotoxicity, nausea and vomiting (30-100%), myelosuppression, electrolyte anomalies, peripheral neuropathy, ototoxicity and anaphylaxis, haemolytic anaemia (rare), optic neuritis (rare), reversible posterior leucoencephalopathy syndrome (rare), seizures (rare), ECG changes (rare) and heart failure (rare).|
|Nedaplatin||||Platinum complex||N/A||IV||As above.||Non-small cell lung cancer, oesophageal cancer, uterine cervical cancer, head and neck cancer and urothelial cancer||Nephrotoxicity, myelosuppression and nausea and vomiting (30-90%).|
|Oxaliplatin||Platinum complex||D (Au)||IV||As above.||Colorectal cancer, oesophageal cancer and gastric cancer||Myelosuppression, peripheral neuropathy, anaphylaxis, nausea and vomiting (30-90%), hypokalaemia, metabolic acidosis, interstitial lung disease (uncommon), ototoxicity (rare), reversible posterior leucoencephalopathy syndrome (rare), immune-mediated cytopenias (rare) and hepatic sinusoidal obstruction syndrome (rare).|
|1.11 Miscellaneous others|
|Altretamine||Triazine||D (Au)||PO||Unclear, reactive intermediates covalently bind to microsomal proteins and DNA, possibly causing DNA damage||Recurrent ovarian cancer||Myelosuppression, peripheral neuropathy, seizures and hepatotoxicity (rare).|
|Bleomycin||Glycopeptide||D (Au)||IM, SC, IA, IV or IP||Inhibits DNA and to a lesser extent RNA synthesis, produces single and double strand breaks in DNA possibly by free radical formation.||Germ cell tumours, squamous cell carcinoma, pancreatic cancer, non-Hodgkin's, pleural sclerosing and Hodgkin's lymphoma.||Pulmonary toxicity, hypersensitivity, scleroderma and Raynaud's phenomenon.|
|Bortezomib||Dipeptidyl boronic acid||C (Au)||IV, SC||Proteasome inhibitor.||Multiple myeloma, mantle cell lymphoma and follicular lymphoma (orphan).||Peripheral neuropathy, neutropenia, thrombocytopenia, anaemia, orthostatic hypotension, hepatitis (uncommon/rare), haemorrhage (uncommon/rare), heart failure (uncommon/rare), seizures (uncommon/rare), progressive multifocal leucoencephalopathy (PML) and hearing loss.|
|Dactinomycin||Polypeptide||D (Au)||IV||Complexes with DNA interfering with DNA-dependent RNA synthesis||Gestational trophoblastic disease, Wilms' tumour and rhabdomyosarcoma||Myelosuppression, anaphylaxis, radiation recall, hepatotoxicity and hepatic sinusoidal obstruction syndrome (common in Wilms' tumour).|
|Estramustine||Nitrogen mustard and oestrogen analogue||D (Au)||PO||Antimicrotubule and oestrogenic actions||Prostate cancer.||Cardiovascular complications, such as ischaemic heart disease, venous thromboembolism, congestive heart failure, pulmonary embolism, myocardial infarction and cerebrovascular failure.|
|Ixabepilone||Epothilone B analogue||D (US)||IV||Promotes tubulin polymerisation and stabilises microtubular function, causing cell cycle arrest at G2/M phase and subsequently induces apoptosis||Locally advanced or metastatic breast cancer.||Myelosuppression, peripheral neuropathy, myocardial ischaemia (uncommon/rare), supraventricular arrhythmia (uncommon/rare) and hypersensitivity reaction (uncommon/rare).|
|Mitomycin||Aziridine||D (Au)||IV||Cross-links DNA||Anal and bladder cancer||Myelosuppression, pulmonary toxicity and haemolytic uraemic syndrome (rare).|
|Procarbazine||Methylhydrazine||D (Au)||IM, IV||Inhibits DNA, RNA and protein synthesis.||Glioma and Hodgkin's lymphoma.||Myelosuppression, neurotoxicity, pulmonary fibrosis (uncommon/rare), pneumonitis (uncommon/rare), haemolysis (uncommon/rare) and hepatic dysfunction (uncommon/rare).|
|2. Targeted antineoplastics|
|2.1 Monoclonal antibodies|
|Alemtuzumab||Protein||B2 (Au)||IV||CD52 antibody induces apoptosis in the tagged cells.||Chronic lymphocytic leukaemia||Pancytopenia, pneumonitis, arrhythmias and hypersensitivity reactions (rare), autoimmune haemolytic anaemia (rare), autoimmune thrombocytopenia (rare) and progressive multifocal leucoencephalopathy (rare).|
|Bevacizumab||Protein||D (Au)||IV||VEGF inhibitor.||Colorectal, breast, ovarian, renal cell and non-squamous non-small cell lung cancer and glioblastoma||Hypertension, thromboembolisms, heart failure, bleeding, neutropenia, thrombocytopenia, GI perforation, fistula formation, hypertensive encephalopathy, pulmonary hypertension, reversible posterior leucoencephalopathy syndrome, nasal septum perforation and osteonecrosis of the jaw.|
|Cetuximab||Protein||D (Au)||IV||EGFR inhibitor.||Squamous cell head and neck cancer or EGFR-positive and KRAS wild-type metastatic colorectal cancer.||Infusion-related reactions, skin reactions, hypomagnesaemia, hypocalcaemia, hypokalaemia, blood clots, interstitial lung disease and aseptic meningitis.|
|Denosumab||Protein||X (US)||SC||RANKL inhibitor.||Osteoporosis, including drug- and cancer-related osteoporosis, giant cell tumour of bone and hypercalcaemia of malignancies||Hypercholesterolaemia, cataract, urinary retention, hypocalcaemia, osteonecrosis of the jaw and anaphylaxis.|
|Gemtuzumab ozogamicin||||Protein||D (US)||IV||CD33 antibody that induces apoptosis of the tagged cell.||Acute myeloid leukaemia||Hepatic veno-occlusive disease, myelosuppression, cytokine release syndrome, hypersensitivity and electrolyte anomalies.|
|Ibritumomab tiuxetan||||Protein||D (US)||IV||CD20 antibody bound with the radioactive isotope, 90Y, induces radiation-dependent cell lysis.||Non-Hodgkin's lymphoma and follicular lymphoma.||Thrombocytopenia, neutropenia, anaemia, hypotension and secondary malignancies.|
|Ipilimumab||Protein||C (Au)||IV||CTLA4 antibody that causes immune system-mediated lysis of the tagged cell||Unresectable or metastatic malignant melanoma.||Life-threatening immune mediated reactions and fever.|
|Ofatumumab||||Protein||C (US)||IV||Anti-CD20 antibody.||Chronic lymphocytic leukaemia||Neutropenia, pneumonia, infusion reactions, cytopenias|
|Panitumumab||Protein||C (Au)||IV||EGFR inhibitor.||RAS (KRAS or NRAS) wild-type metastatic colorectal cancer||Skin reactions, electrolyte anomalies, anaphylaxis and angiooedema (rare).|
|Pertuzumab||Protein||D (Au)||IV||HER2 inhibitor.||HER2-positive breast cancer.||Anaphylaxis, cardiac dysfunction and anaemia.|
|Rituximab||Protein||C (Au)||IV||Anti-CD20 antibody.||CD20-positive B cell non-Hodgkin lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, Wegener's granulomatosis and microscopic polyangiitis||Infusion-related reactions, neutropenia, arrhythmias, infection, thrombocytopenia (uncommon), anaemia (uncommon), angina (uncommon), myocardial infarction (uncommon), heart failure (uncommon), haemolytic anaemia (rare), aplastic anaemia (rare), serum sickness (rare), severe skin conditions (rare), pulmonary infiltrates (rare), pneumonitis (rare), cranial neuropathy (vision or hearing loss; rare) and progressive multifocal leucoencephalopathy (rare).|
|Tositumomab||||Protein||X (US)||IV||Anti-CD20 antibody which is tagged with I131.||Non-Hodgkin's lymphoma||Grade 3-4 cytopenias, methaemoglobinaemia, acute myeloid leukaemia or myelodysplastic syndrome, anaphylaxis and hyperthyroidism.|
|Trastuzumab||Protein||B2 (Au)||IV||Anti-HER2 antibody.||HER2-positive breast cancer, gastric cancer, pancreatic cancer (orphan) and gastro-oesophageal junction cancer.||Cardiac dysfunction, infusion-related reactions, peripheral neuropathy and pulmonary toxicity (rare).|
|2.2 Tyrosine kinase inhibitor|
|Afatinib||||Phenyl quinazolinamine||D (US)||PO||EGFR, HER2 and HER4 inhibitor.||Non-small cell lung cancer.||Diarrhoea, hypokalaemia, interstitial lung disease and hepatotoxicity.|
|Aflibercept||||Protein||C (US)||IV||VEGF and PGF inhibitor.||Colorectal cancer.||Myelosuppression, hypertension, dehydration, blood clots, GI perforation and reversible posterior leucoencephalopathy syndrome (uncommon).|
|Axitinib||||Indazole & pyridine analogue||D (Au)||PO||Multikinase inhibitor.||Renal cell carcinoma||Hypertension, thyroid dysfunction, blood clots, electrolyte disturbances, GI perforation (rare), fistula formation (rare), reversible posterior leucoencephalopathy syndrome (rare) and polycythaemia (uncommon).|
|Bosutinib||||Quinoline carbonitrile analogue||D (Au)||PO||Bcr-Abl and SRc kinase inhibitor.||Chronic myeloid leukaemia||Diarrhoea, thrombocytopenia, neutropenia, hepatotoxicity, QT interval prolongation, kidney failure, pleural effusion, pericarditis (uncommon/rare), acute pancreatitis (uncommon/rare), GI haemorrhage (uncommon/rare), anaphylactic shock (uncommon/rare), acute pulmonary oedema (uncommon/rare), respiratory failure (uncommon/rare), pulmonary hypertension(uncommon/rare) and erythema multiforme (uncommon/rare).|
|Aminopyridine||D (US)||PO||ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and Recepteur d'Origine Nantais (RON) inhibitor.||Non-small cell lung cancer||Lymphopenia, neutropenia, hypophosphataemia, hypokalaemia, peripheral neuropathy, blood clots, QT interval prolongation, bradycardia, pneumonia, pneumonitis, kidney cyst, ARDS and liver failure.|
|Dasatinib||Piperazine||D (Au)||PO||BCR-ABL, SRC family, c-Kit, EPHA2 and PDGFR-β kinase inhibitor.||Philadelphia positive chronic myeloid leukaemia and acute lymphoblastic leukaemia.||Fluid retention, myelosuppression, haemorrhage, hypertension, electrolyte anomalies, cardiac dysfunction (rare), heart failure (rare), myocardial infarction, arrhythmia (rare), prolonged QT interval (rare), kidney failure (rare), hypersensitivity (rare) and hepatic failure (rare).|
|Erlotinib||Quinazoline||C (Au)||PO||EGFR inhibitor.||Non-small cell lung cancer and pancreatic cancer.||Skin reactions, diarrhoea, GI bleeds, anaemia, dehydration, interstitial lung disease (uncommon), hepatic failure (rare), hepatorenal syndrome (rare), GI perforation (rare) and ulcerative keratitis (rare).|
|Gefitinib||Quinazoline||C (Au)||PO||EGFR inhibitor.||EGFR-mutation positive non-small cell lung cancer.||Skin reactions, diarrhoea, dehydration, haemorrhage, interstitial lung disease (uncommon), pancreatitis (uncommon), hepatitis (uncommon), allergy (uncommon), hepatic failure (rare), toxic epidermal necrolysis (rare) and Stevens-Johnson syndrome (rare).|
|Imatinib||Pyrimidine and piperazine.||D (Au)||PO||Bcr-Abl kinase inhibitor.||Philadelphia chromosome-positive acute lymphoblastic leukaemia, chronic myeloid leukaemia, GI stromal tumour and myelodysplastic/myeloproliferative diseases.||Myelosuppression, fluid retention, GI bleeding, electrolyte anomalies, left ventricular dysfunction (uncommon), heart failure (uncommon), pulmonary oedema (uncommon), kidney failure (uncommon), angiooedema (rare), anaphylaxis (rare), GI perforation (rare), hepatotoxicity (rare), avascular necrosis (rare), myopathy (rare) and rhabdomyolysis (rare).|
|Lapatinib||Quinazoline||C (Au)||PO||HER2 inhibitor.||HER2-positive breast cancer, stomach cancer (orphan) and oesophageal cancer (orphan).||Diarrhoea, interstitial lung disease (uncommon), hepatotoxicity (uncommon) and anaphylaxis (rare).|
|Nilotinib||Imidazole||D (Au)||PO||Bcr-Abl kinase inhibitor.||Chronic myeloid leukaemia.||Myelosuppression, electrolyte disturbances, hyperglycaemia, prolonged QT interval (uncommon), peripheral arterial occlusive disease (uncommon), pancreatitis (uncommon), pleural effusion (uncommon) and pericardial effusion (uncommon).|
|Pazopanib||Indazole||D (Au)||PO||Multikinase inhibitor, including c-KIT, FGFR, PDGFR and VEGFR.||Renal cell carcinoma and soft tissue sarcoma.||Hypertension, QT interval prolongation, haemorrhage, blood clots, neutropenia, thrombocytopenia, neutropenia, thrombocytopenia, elevated thyroid-stimulating hormone, hypothyroidism, electrolyte disturbances, hypo- or hyperglycaemia, torsades de pointes (uncommon), heart failure (uncommon), hepatic failure (uncommon), GI perforation (uncommon), fistula formation (uncommon) and reversible posterior leucoencephalopathy syndrome (rare).|
|Ponatinib||||Imidazopyridazine||D (US)||PO||Multikinase inhibitor (BEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET, TIE2 and FLT3), that also inhibits T135I Bcr-Abl kinase.||T135I positive Chronic myeloid leukaemia and Philadelphia chromosome positive acute lymphoblastic leukaemia.||Hypertension, neutropenia, leucopenia, anaemia, thrombocytopenia, lymphopenia, pleural effusion, heart failure, peripheral neuropathy, haemorrhage, blood clots, pancreatitis and infection.|
|4-phenoxypyridine||D (US)||PO||Multikinase inhibitor for RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, Trk2A, Eph2A, RAF-1, BRAF, BRAFV600E, SAPK2, PTK5, and Bcr-Abl.||Colorectal cancer and GI stromal tumours.||Anaemia, lymphopenia, thrombocytopenia, electrolyte anomalies, hepatotoxicity, hypertension, hypothyroidism, neutropenia, myocardial ischaemia or infarction.|
|Pyrimidinylpyrazole||C (Au)||PO||JAK1 and JAK2 inhibitor.||Myelofibrosis and pancreatic cancer (orphan).||Anaemia and thrombocytopenia.|
|Sorafenib||4-phenoxypyridine||D (Au)||PO||Multikinase inhibitor (including VEGF and PDGF receptor kinases).||Renal cell carcinoma and hepatocellular carcinoma.||Hypertension, skin reactions, bleeding, neutropenia, thrombocytopenia, lymphopenia, peripheral neuropathy, thyroid dysfunction, electrolyte anomalies, myocardial ischaemia or infarctions, heart failure (uncommon), GI perforation (uncommon), pancreatitis (uncommon), reversible posterior leucoencephalopathy syndrome (rare), hepatitis (rare), nephrotic syndrome (rare) and prolonged QT interval (rare).|
|Sunitinib||Oxindole||D (Au)||PO||Multikinase inhibitor (including VEGF & PDGF receptor tyrosine kinases)||renal cell carcinoma, GI stromal tumour and pancreatic neuroendocrine tumour||Neutropenia, thrombocytopenia, lymphopenia, hypertension, left ventricular dysfunction, heart failure, blood clots, thyroid dysfunction, electrolyte anomalies, pancreatitis (uncommon), hepatic failure (uncommon), prolonged QT interval (rare), torsades de pointes (rare), GI perforation (rare), fistula formation (rare), seizures (rare), reversible posterior leucoencephalopathy syndrome (rare), haemolytic uraemic syndrome (rare), thrombotic thrombocytopenic purpura (rare), nephrotic syndrome (rare), hypersensitivity (rare), angiooedema (rare), toxic epidermal necrolysis (rare) and Stevens-Johnson syndrome (rare).|
|Vandetanib||Quinazoline||D (US)||PO||Tyrosine kinase inhibitor (TKI) with selective activity against RET, VEGFR-2 and EGFR||Medullary thyroid cancer.||Diarrhoea, hypertension, QT interval prolongation, depression, electrolyte anomalies, hypothyroidism and GI perforation (uncommon).|
|2.3 mTOR inhibitors|
|Everolimus||Sirolimus analogue.||C (Au)||PO||mTOR inhibitor.||Renal cell cancer, pancreatic neuroendocrine tumour and breast cancer||Pleural effusion, hyperglycaemia, hypercholesterolaemia, hypertriglyceridaemia, neutropenia, lymphopenia, thrombocytopenia, anaemia, bleeding, kidney failure, hypokalaemia, hypophosphataemia, pneumonitis, impaired wound healing (uncommon), anaphylaxis (rare) and angiooedema (rare).|
|Temsirolimus||Sirolimus analogue.||D (Au)||IV||mTOR inhibitor.||Renal cell cancer and mantle cell lymphoma.||Infusion reactions, impaired wound healing, hyperglycaemia, hypercholesterolaemia, hypertriglyceridaemia, neutropenia, lymphopenia, thrombocytopenia, anaemia, bleeding, kidney failure, hypokalaemia, hypophosphataemia, pneumonitis, bowel perforation (uncommon) and intracerebral bleeding and Stevens-Johnson syndrome (rare).|
|Alitretinoin||9-cis retinoic acid||D (US)||Topical||Retinoic acid receptor (RAR) and retinoid X receptor (RXR) agonist.||Kaposi's sarcoma.||Oedema, rashes|
|Bexarotene||Phenethylnaphthalene||X (US)||PO, topical||RXR agonist.||Cutaneous T cell lymphoma||Leucopenia, anaemia, lactic dehydrogenase increased, hypochromic anaemia, hyperlipidaemia, hypercholesteraemia, hypothyroidism, haemorrhage, hypertension and kidney dysfunction.|
|Isotretinoin||13-cis retinoic acid||D (Au, topical), X (Au, oral)||PO, topical||RXR & RAR agonist.||Neuroblastoma and acne.||Topical: Skin reactions, blood lipid anomalies, increased platelet count and osteoporosis. Oral: Anaemia, Red blood cell sedimentation rate increased, thrombocytopenia, thrombocytosis, neutropenia, anaphylaxis, hypersensitivity, diabetes mellitus, hyperuricaemia, psychiatric disturbances (rare), convulsions (very rare), conjunctivitis, vasculitis (very rare), GI haemorrhage (very rare), hepatitis (very rare), erythema multiforme, stevens-Johnson Syndrome, toxic epidermal necrolysis, arthritis (very rare), rhabdomyolysis and glomerulonephritis (very rare).|
|Tamibarotene||||Naphthalene||N/A||PO||RAR agonist.||Refractory acute promyelocytic leukaemia and Alzheimer's disease.||Hypercholesterolaemia, hypertriglyceridaemia, gastrointestinal disturbances, liver damage, leucocytosis and differentiation syndrome.|
|Tretinoin||all-trans retinoic acid||D (Au, topical), X (Au, oral)||PO, topical||RXR & RAR agonist.||Acne and acute promyelocytic leukaemia.||Oral: Differentiation syndrome, hyperleucocytosis, elevated cholesterol and triglycerides, arrhythmias, pancreatitis, elevated liver enzymes, thrombosis, intracranial hypertension and pseudotumour cerebri (mainly in children), anxiety, depression and genital ulceration (rare). Topical: Erythema.|
|2.4 Immunomodulatory Agents (IMiDs)|
|Lenalidomide||Thalidomide analogue||X (Au)||PO||Numerous actions; anti-angiogenesis (via inhibition of VEGF release), anti-TNF, IL-6 and pro-IL-2, IFN-γ effects. Also stimulates T cells and apoptosis in cancer cells.||Multiple myeloma||Blood clots, neutropenia (dose-limiting), thrombocytopenia (dose-limiting), anaemia, infection, hypotension, hypokalaemia, hypothyroidism, Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema, pneumonitis, hepatotoxicity and secondary malignancies (mostly myelodysplastic syndrome and acute myeloid leukaemia).|
|Pomalidomide||Thalidomide analogue||X (US)||PO||As above.||Multiple myeloma and systemic sclerosis (orphan).||Neutropenia, anaemia, pneumonia, thrombocytopenia, hypercalcaemia, hyperglycaemia, kidney failure, lymphopenia, hyponatraemia, hypocalcaemia, hypokalaemia, peripheral neuropathy and thromboembolism.|
|Thalidomide||Thalidomide||X (Au)||PO||As above.||Multiple myeloma, erythema nodosum leprosum and the following orphan indications: graft versus host disease, mycobacterial infection, recurrent aphthous ulcers, severe recurrent aphthous stomatitis, primary brain malignancies, HIV-associated wasting syndrome, Crohn's disease, Kaposi's sarcoma, myelodysplastic syndrome and haematopoietic stem cell transplantation.||Peripheral neuropathy, depression, thromboembolism, bradycardia, orthostatic hypotension, leucopenia, hypothyroidism, thrombocytopenia (uncommon), Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare), pneumonitis (rare), hepatotoxicity (rare) and hearing loss (rare).|
|2.5 Histone deacetylase inhibitors|
|Romidepsin||||Depsipeptide||D (US)||IV||Histone deacetylase inhibitor, hence inducing alterations in gene expression in the affected cells.||Peripheral and cutaneous T cell lymphoma.||Electrolyte anomalies, anaemia, thrombocytopenia, neutropenia, lymphopenia and ECG anomalies.|
|Valproate[Note 1]|| 
|Branched short-chain fatty acids.||D (Au)||PO, IV||As above.||Migraine prophylaxis, mania, epilepsy, fragile X syndrome(orphan), familial adenomatous polyposis (orphan) and the following off-label uses: cervical cancer, melanoma, mesothelioma, acute myeloid leukaemia and myelodysplastic syndrome.||Hyperammonaemia, thrombocytopenia, polycystic ovaries, SIADH (uncommon), hepatic failure (rare), pancreatitis (rare), leucopenia (rare), neutropenia (rare), pure red cell aplasia (rare), agranulocytosis (rare), extrapyramidal syndrome (rare), reduced BMD with long-term use, pleural effusion (rare) and multiorgan hypersensitivity reaction (rare).|
|Vorinostat||||Phenyloctanediamide||D (US)||PO||As above.||As per romidepsin.||Thrombocytopenia, anaemia, QT interval prolongation and pulmonary embolism.|
|2.6 Other Agents|
|Anagrelide||Imidazoquinazoline||B3 (Au)||PO||Phosphodiesterase 3 inhibitor.||Essential thrombocythaemia||Fluid retention, palpitations, tachycardia, hepatotoxicity (uncommon), heart failure (uncommon), hypertension (uncommon), arrhythmia (uncommon), syncope (uncommon), cardiomyopathy (rare), cardiomegaly (rare), MI (rare), pulmonary hypertension (rare), interstitial lung disease (rare) and pancreatitis (rare).|
|Arsenic trioxide[Note 2]||Arsenic compound||X (Au)||IV||Not fully understood. Induces partial differentiation and promotes apoptosis of leukaemic cells and may also inhibit angiogenesis.||Refractory or relapsed acute promyelocytic leukaemia. Orphan indications include: acute myeloid leukaemia, chronic lymphocytic leukaemia, malignant glioma, myelodysplastic syndrome, multiple myeloma, liver cancer and chronic myeloid leukaemia.||Differentiation syndrome, hyperleucocytosis, neutropenia, thrombocytopenia, ventricular tachycardia, prolonged QT interval, torsades de pointes, complete atrioventricular block, peripheral neuropathy, hyperglycaemia, hypokalaemia, hypomagnesaemia, elevation of bilirubin or aminotransferases, hepatotoxicity and secondary malignancies.|
|Protein||D (Au)||IM, IV||Catalyses the conversion of the amino acid L-asparagine to aspartic acid and thereby reduces the availability of L-asparagine to leukaemic cells. Unlike normal cells, certain types of leukaemic cells do not synthesise L-asparagine, which is essential for cell growth and survival.||Acute lymphoblastic leukaemia and lymphoblastic lymphoma.||Allergic reactions, haemorrhagic and thrombotic events, uraemia, pancreatitis, hyperglycaemia, hyperammonaemia, acute kidney failure and diabetic ketoacidosis.|
| BCG vaccine
|Protein||B2 (Au)||IB||Live, attenuated Mycobacterium bovis, which produces a local inflammatory reaction, resulting in elimination or reduction of superficial tumour lesions of the bladder.||Bladder cancer||Cystitis, BCG infection and contracted bladder.|
|Denileukin diftitox|| 
|Protein||C (US)||IV||Interleukin 2 combined with diphtheria toxin which binds to the interleukin receptor on immune cells and introduces the diphtheria toxin into the cell.||Cutaneous T cell lymphoma and peripheral T cell lymphoma (orphan).||Infusion reactions, hypocalcaemia, hypotension, thrombocytopenia, Acute renal insufficiency (uncommon/rare), Hyper/hypothyroidism (uncommon/rare), pancreatitis (uncommon/rare) and toxic epidermal necrolysis (uncommon/rare).|
|Vemurafenib||Pyrrolopyridine||D (Au)||PO||BRAF kinase inhibitor.||BRAF kinase mutation V600E-positive Metastatic melanoma.||Skin reactions, secondary malignancies (mostly squamous cell carcinoma), anaphylaxis (rare) and hypotension (rare).|
IM – Intramuscular. IV – Intravenous. IA – Intra-arterial. SC – Subcutaneous. PO – Per os, oral. IP – Intrapleural. IB – Intrabladder. Preg. cat. - Pregnancy category. The preferred pregnancy category is Australian, but if it is unavailable the pregnancy category given is American.
List of the top 10 best-selling cancer drugs of 2013:
|No.||2013 Global Sales||INN||Trade names||Companies||Indications|
|1||$7.78 billion||Rituximab||Rituxan/MabThera||Roche, Pharmstandard||non-Hodgkin's lymphoma, CLL|
|2||$6.75 billion||Bevacizumab||Avastin||Roche||Colorectal, lung, ovarian and brain cancer|
|3||$6.56 billion||Trastuzumab||Herceptin||Roche||Breast, esophagus and stomach cancer|
|4||$4.69 billion||Imatinib||Gleevec||Novartis||Leukemia, GI cancer|
|5||$1.09 billion||Lenalidomide||Revlimid||Celgene, Pharmstandard||Multiple myeloma, mantle cell lymphoma|
|6||$2.7 billion||Pemetrexed||Alimta||Eli Lilly||Lung cancer|
|7||$2.6 billion||Bortezomib||Velcade||Johnson & Johnson, Takeda, Pharmstandard||Multiple myeloma|
|8||$1.87 billion||Cetuximab||Erbitux||Merck KGaA, Bristol-Myers Squibb||Colon and head and neck cancer|
|9||$1.73 billion||Leuprorelin||Lupron, Eligard||AbbVie and Takeda; Sanofi and Astellas Pharma||Prostate and ovarian cancer|
|10||$1.7 billion||Abiraterone||Zytiga||Johnson & Johnson||Prostate cancer|
- Anti-Cancer Drugs (journal)
- Cancer and nausea
- Cancer-related fatigue
- Chemo brain
- Chemotherapy regimens
- Experimental cancer treatments
- Safe Handling of Hazardous Drugs
- Hyperthermia therapy
- National Comprehensive Cancer Network
- Radiation induced cognitive decline
- Krumbhaar EB (1919). "Role of the blood and the bone marrow in certain forms of gas poisoning". JAMA 72: 39–41. doi:10.1001/jama.1919.26110010018009f.
- Fenn JE, Udelsman R (Mar 2011). "First use of intravenous chemotherapy cancer treatment: rectifying the record". Journal of the American College of Surgeons 212 (3): 413–417. PMID 21247779. doi:10.1016/j.jamcollsurg.2010.10.018.
- Goodman LS; Wintrobe MM; Dameshek W; Goodman MJ; Gilman A; McLennan MT (1946). "Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders". JAMA 132 (3): 126–132. doi:10.1001/jama.1946.02870380008004.
- Faguet, p. 71
- Joensuu H (Mar 2008). "Systemic chemotherapy for cancer: from weapon to treatment". The Lancet. Oncology 9 (3): 304. PMID 18308256. doi:10.1016/S1470-2045(08)70075-5.
- DeVita VT, Chu E (Nov 2008). "A history of cancer chemotherapy". Cancer Research 68 (21): 8643–53. PMID 18974103. doi:10.1158/0008-5472.CAN-07-6611.
- Nichols HJ, Walker JE (Mar 1923). "EXPERIMENTAL OBSERVATIONS ON THE PROPHYLAXIS AND TREATMENT OF SYPHILIS". The Journal of Experimental Medicine 37 (4): 525–42. PMC 2128372. PMID 19868743. doi:10.1084/jem.37.4.525.
- Hanahan D, Weinberg RA (Jan 2000). "The hallmarks of cancer". Cell 100 (1): 57–70. PMID 10647931. doi:10.1016/S0092-8674(00)81683-9.
- Hodgson S (Jan 2008). "Mechanisms of inherited cancer susceptibility". Journal of Zhejiang University. Science. B 9 (1): 1–4. PMC 2170461. PMID 18196605. doi:10.1631/jzus.B073001.
- Perera FP (Nov 1997). "Environment and cancer: who are susceptible?". Science 278 (5340): 1068–73. Bibcode:1997Sci...278.1068P. PMID 9353182. doi:10.1126/science.278.5340.1068.
- Randall, pp, 93-94
- Kehe K, Balszuweit F, Steinritz D, Thiermann H (Sep 2009). "Molecular toxicology of sulfur mustard-induced cutaneous inflammation and blistering". Toxicology 263 (1): 12–9. PMID 19651324. doi:10.1016/j.tox.2009.01.019.
- Malhotra V, Perry MC (2003). "Classical chemotherapy: mechanisms, toxicities and the therapeutic window". Cancer Biology & Therapy 2 (4 Suppl 1): S2–4. PMID 14508075.
- Makin G, Hickman JA (Jul 2000). "Apoptosis and cancer chemotherapy". Cell and Tissue Research 301 (1): 143–52. Bibcode:1994RSPTB.345..319H. PMID 10928287. doi:10.1007/s004419900160.
- Corrie PG, Pippa G. (2008). "Cytotoxic chemotherapy: clinical aspects". Medicine 36 (1): 24–28. doi:10.1016/j.mpmed.2007.10.012.
- Siddik ZH (2005). Mechanisms of Action of Cancer Chemotherapeutic Agents: DNA-Interactive Alkylating Agents and Antitumour Platinum-Based Drugs. John Wiley & Sons, Ltd. doi:10.1002/0470025077.chap84b.
- Lind M.J., M.J. (2008). "Principles of cytotoxic chemotherapy". Medicine 36 (1): 19–23. doi:10.1016/j.mpmed.2007.10.003.
- Damia G, D'Incalci M (Sep 1998). "Mechanisms of resistance to alkylating agents". Cytotechnology 27 (1-3): 165–73. PMC 3449574. PMID 19002790. doi:10.1023/A:1008060720608.
- Giorgi-Renault, S., Renault J., Baron M., Gebel-Servolles, P., Delic, J., Cros S., Paoletti C., Heterocyclic quinones XIII. Dimerization in the series of 5,8-quinazolinediones: Synthesis and anti tumor effects of bis(4-amino-5,8-quinazolinediones), Chem. Pharm. Bull., 36 (10), 3933-3947 (1988).
- Takimoto CH, Calvo E."Principles of Oncologic Pharmacotherapy" in Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (Eds) Cancer Management: A Multidisciplinary Approach. 11 ed. 2008.
- Parker WB (Jul 2009). "Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer". Chemical Reviews 109 (7): 2880–93. PMC 2827868. PMID 19476376. doi:10.1021/cr900028p.
- Wood, p. 11
- Airley, pp. 55-59
- Adjei AA (Jun 2004). "Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent". Clinical Cancer Research 10 (12 Pt 2): 4276s–4280s. PMID 15217974. doi:10.1158/1078-0432.CCR-040010.
- Wagstaff AJ, Ibbotson T, Goa KL (2003). "Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer". Drugs 63 (2): 217–36. PMID 12515569. doi:10.2165/00003495-200363020-00009.
- Rowinsky EK, Donehower RC (Oct 1991). "The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics". Pharmacology & Therapeutics 52 (1): 35–84. PMID 1687171. doi:10.1016/0163-7258(91)90086-2.
- Yue QX, Liu X, Guo DA (Aug 2010). "Microtubule-binding natural products for cancer therapy". Planta Medica 76 (11): 1037–43. PMID 20577942. doi:10.1055/s-0030-1250073.
- Damayanthi Y, Lown JW (Jun 1998). "Podophyllotoxins: current status and recent developments". Current Medicinal Chemistry 5 (3): 205–52. PMID 9562603.
- Liu YQ, Yang L, Tian X, Cong; Zhang, Wei; Qian, Zhengnan; Hua, Zhong; Zhao, Qibo; Sui, Yu; Su, Wenhui; Zhang, Ming; Liu, Zhuhong; Liu, Guodong; Wu, Guangheng (2007). "Podophyllotoxin: current perspectives". Curr Bioactive Compounds 3 (1): 37–66. doi:10.1016/j.jallcom.2006.06.070.
- Lodish H, Berk A, Zipursky SL et al. (2000). Molecular Cell Biology. 4th edition. The Role of Topoisomerases in DNA Replication. New York: W. H. Freeman.
- Goodsell DS (2002). "The molecular perspective: DNA topoisomerases". Stem Cells 20 (5): 470–1. PMID 12351817. doi:10.1634/stemcells.20-5-470.
- Nitiss JL (May 2009). "Targeting DNA topoisomerase II in cancer chemotherapy". Nature Reviews. Cancer 9 (5): 338–50. PMC 2748742. PMID 19377506. doi:10.1038/nrc2607.
- Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (Jun 2004). "Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity". Pharmacological Reviews 56 (2): 185–229. PMID 15169927. doi:10.1124/pr.56.2.6.
- Sobell HM (Aug 1985). "Actinomycin and DNA transcription". Proceedings of the National Academy of Sciences of the United States of America 82 (16): 5328–31. Bibcode:1985PNAS...82.5328S. PMC 390561. PMID 2410919. doi:10.1073/pnas.82.16.5328.
- Dorr RT (Apr 1992). "Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics". Seminars in Oncology 19 (2 Suppl 5): 3–8. PMID 1384141.
- Airley, p. 87
- Verweij J, Pinedo HM (Oct 1990). "Mitomycin C: mechanism of action, usefulness and limitations". Anti-Cancer Drugs 1 (1): 5–13. PMID 2131038. doi:10.1097/00001813-199010000-00002.
- Wood, pp. 17-18
- Perry, p. 42
- Epstein RJ (Aug 2005). "Maintenance therapy to suppress micrometastasis: the new challenge for adjuvant cancer treatment". Clinical Cancer Research 11 (15): 5337–41. PMID 16061845. doi:10.1158/1078-0432.CCR-05-0437.
- Skeel RT (2003). Handbook of Cancer Chemotherapy (paperback) (6th ed.). Lippincott Williams & Wilkins. ISBN 0-7817-3629-3.
- Chabner B, Longo DL (2005). Cancer Chemotherapy and Biotherapy: Principles and Practice (4th ed.). Philadelphia: Lippincott Willians & Wilkins. ISBN 0-7817-5628-6.
- Du Bois D; Du Bois EF. "A formula to estimate the approximate surface area if height and weight be known. 1916." 5 (5). Archives Internal Medicine. pp. 303–11.
- Felici A.; J. Verweij; A. Sparreboom (2002). "Dosing strategies for anticancer drugs: the good, the bad and body-surface area" 38 (13). Eur J Cancer. pp. 1677–84.
- Kaestner SA, Sewell GJ (Feb 2007). "Chemotherapy dosing part I: scientific basis for current practice and use of body surface area". Clinical Oncology 19 (1): 23–37. PMID 17305252. doi:10.1016/j.clon.2006.10.010.
- Donald Pinkel (August 1958). "The Use of Body Surface Area as a Criterion of Drug Dosage in Cancer Chemotherapy" 18 (7). Cancer Res. pp. 853–6.
- Gurney H (Apr 2002). "How to calculate the dose of chemotherapy". British Journal of Cancer 86 (8): 1297–302. PMC 2375356. PMID 11953888. doi:10.1038/sj.bjc.6600139.
- Beumer JH, Chu E, Salamone SJ (Nov 2012). "Body-surface area-based chemotherapy dosing: appropriate in the 21st century?". Journal of Clinical Oncology 30 (31): 3896–7. PMID 22965963. doi:10.1200/JCO.2012.44.2863.
- Baker SD; Verweij J; Rowinsky EK; Donehower RC; Schellens JH; Grochow LB; Sparreboom A (2002). "Role of body surface area in dosing of investigational anticancer agents in adults, 1991–2001" 94 (24). J Natl Cancer Inst. pp. 1883–8.
- Gamelin EC; Delva R; Jacob J; Merrouche Y; Raoul JL; Pezet D; Dorval E; Piot G; Morel A; Boisdron-Celle M (2008). "Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer" 26 (13). J Clin Oncol. pp. 2099–2105.
- Saam J; Critchfield GC; Hamilton SA; Roa BB; Wenstrup RJ; Kaldate RR (2011). "Body Surface Area-based Dosing of 5-Fluorouracil Results in Extensive Interindividual Variability in 5-Fluorouracil Exposure in Colorectal Cancer Patients on FOLFOX Regimens" 10 (3). Clin Colorectal Cancer. pp. 203–206.
- Capitain O; Asevoaia A; Boisdron-Celle M; Poirier AL; Morel A; Gamelin E (2012). "Individual Fluorouracil Dose Adjustment in FOLFOX Based on Pharmacokinetic Follow-Up Compared With Conventional Body-Area-Surface Dosing: A Phase II, Proof-of-Concept Study" 11 (4). Clin Colorectal Cancer. pp. 263–267.
- Kaldate RR; Haregewoin A; Grier CE; Hamilton SA; McLeod HL. "Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6" 17 (3). Oncologist, 2012. pp. 296–302.
- Hunter RJ, Navo MA, Thaker PH, Bodurka DC, Wolf JK, Smith JA (Feb 2009). "Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA)". Cancer Treatment Reviews (Cancer Treat Rev) 35 (1): 69–78. PMID 18922643. doi:10.1016/j.ctrv.2008.07.005.
- Macbeth, p. 4
- Buffery, PJ; Allen, KM; Chin, PKL; Moore, GA; Barclay, ML; Begg, EJ (2014). "Thirteen Years’ Experience of Pharmacokinetic Monitoring and Dosing of Busulfan: Can the Strategy Be Improved?" 36 (1). Ther Drug Monit. pp. 86–92.
- Bartelink IH; Bredius RG; Belitser SV; Suttorp MM; Bierings M; Knibbe CA; Egeler M; Lankester AC; Egberts AC; Zwaveling J; Boelens JJ. "Association Between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan Before Hematopoietic Stem Cell Transplantation" 36 (1). Ther Drug Monit. pp. 93–99.
- "ARK™ Methotrexate Assay". Ark Diagnostics.
- "Customizing Chemotherapy for Better Cancer Care". My Care Diagnostics.
- "A Brief History of BSA Dosing". My Care Diagnostics.
- Wood, Miriam; David Brighton (2005). The Royal Marsden Hospital handbook of cancer chemotherapy: a guide for the multidisciplinary team. St. Louis, Mo: Elsevier Churchill Livingstone. pp. 93–94. ISBN 0-443-07101-2.
- Wood, pp. 113-118
- Moreno-Ramirez D, de la Cruz-Merino L, Ferrandiz L, Villegas-Portero R, Nieto-Garcia A (2010). "Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety". The Oncologist 15 (4): 416–27. PMC 3227960. PMID 20348274. doi:10.1634/theoncologist.2009-0325.
- Verhoef C, de Wilt JH, ten Hagen TL, Eggermont AM (Oct 2008). "Isolated hepatic perfusion for the treatment of liver tumors: sunset or sunrise?". Surgical Oncology Clinics of North America 17 (4): 877–94, xi. PMID 18722924. doi:10.1016/j.soc.2008.04.007.
- Hendriks JM, Van Schil PE (1998). "Isolated lung perfusion for the treatment of pulmonary metastases". Surgical Oncology 7 (1-2): 59–63. PMID 10421507. doi:10.1016/S0960-7404(98)00028-0.
- Chitwood K, Etzkorn J, Cohen G (Sep 2013). "Topical and intralesional treatment of nonmelanoma skin cancer: efficacy and cost comparisons". Dermatologic Surgery 39 (9): 1306–16. PMID 23915332. doi:10.1111/dsu.12300.
- Airley, p. 265
- Huang, p. 130
- Elad S, Zadik Y, Hewson I, Hovan A, Correa ME, Logan R, Elting LS, Spijkervet FK, Brennan MT (Aug 2010). "A systematic review of viral infections associated with oral involvement in cancer patients: a spotlight on Herpesviridea". Supportive Care in Cancer 18 (8): 993–1006. PMID 20544224. doi:10.1007/s00520-010-0900-3.
- "Coriolus Versicolor". Cancer.org. 2008-06-10. Retrieved 7 August 2012.
- Davila ML (Jan 2006). "Neutropenic enterocolitis". Current Opinion in Gastroenterology 22 (1): 44–7. PMID 16319675.
- Keidan RD, Fanning J, Gatenby RA, Weese JL (Mar 1989). "Recurrent typhlitis. A disease resulting from aggressive chemotherapy". Diseases of the Colon and Rectum 32 (3): 206–9. PMID 2920627. doi:10.1007/BF02554529.
- Gibson RJ, Keefe DM (Sep 2006). "Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies". Supportive Care in Cancer 14 (9): 890–900. PMID 16604351. doi:10.1007/s00520-006-0040-y.
- Groopman JE, Itri LM (Oct 1999). "Chemotherapy-induced anemia in adults: incidence and treatment". Journal of the National Cancer Institute 91 (19): 1616–34. PMID 10511589. doi:10.1093/jnci/91.19.1616.
- Henry DH (Jul 2006). "The role of intravenous iron in cancer-related anemia". Oncology 20 (8 Suppl 6): 21–4. PMID 16925107.
- Rodgers GM, Becker PS, Bennett CL, Cella D, Chanan-Khan A, Chesney C, Cleeland C, Coccia PF, Djulbegovic B, Garst JL, Gilreath JA, Kraut EH, Lin WC, Matulonis U, Millenson M, Reinke D, Rosenthal J, Sabbatini P, Schwartz RN, Stein RS, Vij R (Jul 2008). "Cancer- and chemotherapy-induced anemia". Journal of the National Comprehensive Cancer Network 6 (6): 536–64. PMID 18597709.
- Vadhan-Raj S (Jan 2009). "Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents". Seminars in Hematology 46 (1 Suppl 2): S26–32. PMID 19245931. doi:10.1053/j.seminhematol.2008.12.007.
- Sekhon SS, Roy V (May 2006). "Thrombocytopenia in adults: A practical approach to evaluation and management". Southern Medical Journal 99 (5): 491–8; quiz 499–500, 533. PMID 16711312. doi:10.1097/01.smj.0000209275.75045.d4.
- Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, Cimprich B, Cleeland C, Eisenberger MA, Escalante CP, Jacobsen PB, Kaldor P, Ligibel JA, Murphy BA, O'Connor T, Pirl WF, Rodler E, Rugo HS, Thomas J, Wagner LI (Aug 2010). "Cancer-related fatigue". Journal of the National Comprehensive Cancer Network 8 (8): 904–31. PMID 20870636.
- Franklin DJ, Packel L (Mar 2006). "Cancer-related fatigue". Archives of Physical Medicine and Rehabilitation 87 (3 Suppl 1): S91–3; quiz S94–5. PMID 16500197. doi:10.1016/j.apmr.2005.12.015.
- Cramp F, Byron-Daniel J (2012). Cramp, Fiona, ed. "Exercise for the management of cancer-related fatigue in adults". The Cochrane Database of Systematic Reviews 11: CD006145. PMID 23152233. doi:10.1002/14651858.CD006145.pub3.
- Gill, Paula; Grothey, Axel; Loprinzi, Charles (2006). "Nausea and Vomiting in the Cancer Patient". Oncology: 1482–1496. ISBN 978-0-387-24291-0. doi:10.1007/0-387-31056-8_83. Retrieved 2 September 2011.
Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families.
- Chadha V, Shenoi SD (2003). "Hair loss in cancer chemotherapeutic patients". Indian Journal of Dermatology, Venereology and Leprology 69 (2): 131–132. PMID 17642856.
- Lemieux J (Oct 2012). "Reducing chemotherapy-induced alopecia with scalp cooling". Clinical Advances in Hematology & Oncology 10 (10): 681–682. PMID 23187775.
- Shapiro J, Price VH (Apr 1998). "Hair regrowth. Therapeutic agents". Dermatologic Clinics 16 (2): 341–356. PMID 9589208. doi:10.1016/S0733-8635(05)70017-6.
- Al-Mohanna H, Al-Khenaizan S (2010). "Permanent alopecia following cranial irradiation in a child". Journal of Cutaneous Medicine and Surgery 14 (3): 141–143. PMID 20487675.
- Can G, Demir M, Erol O, Aydiner A (Jun 2013). "A comparison of men and women's experiences of chemotherapy-induced alopecia". European Journal of Oncology Nursing 17 (3): 255–60. PMID 22901547. doi:10.1016/j.ejon.2012.06.003.
- Trüeb RM (Mar 2009). "Chemotherapy-induced alopecia". Seminars in Cutaneous Medicine and Surgery 28 (1): 11–4. PMID 19341937. doi:10.1016/j.sder.2008.12.001.
- Chon SY, Champion RW, Geddes ER, Rashid RM (Jul 2012). "Chemotherapy-induced alopecia". Journal of the American Academy of Dermatology 67 (1): e37–47. PMID 22178150. doi:10.1016/j.jaad.2011.02.026.
- U. Rüther, C. Nunnensiek, H.-J. Schmoll,Secondary Neoplasias following Chemotherapy, Radiotherapy, and Immunosuppression, Contributions to Oncology (Beiträge zur Onkologie); Vol 55, 2000, ISBN 3-8055-7116-X
- Hijiya N, Hudson MM, Lensing S, Zacher M, Onciu M, Behm FG, Razzouk BI, Ribeiro RC, Rubnitz JE, Sandlund JT, Rivera GK, Evans WE, Relling MV, Pui CH (Mar 2007). "Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia". Jama 297 (11): 1207–1215. PMID 17374815. doi:10.1001/jama.297.11.1207.
- Brydøy M, Fosså SD, Dahl O, Bjøro T (2007). "Gonadal dysfunction and fertility problems in cancer survivors". Acta Oncologica 46 (4): 480–9. PMID 17497315. doi:10.1080/02841860601166958.
- Morgan S, Anderson RA, Gourley C, Wallace WH, Spears N (2012). "How do chemotherapeutic agents damage the ovary?". Human Reproduction Update 18 (5): 525–35. PMID 22647504. doi:10.1093/humupd/dms022.
- Gurgan T, Salman C, Demirol A (Oct 2008). "Pregnancy and assisted reproduction techniques in men and women after cancer treatment". Placenta. 29 Suppl B: 152–9. PMID 18790328. doi:10.1016/j.placenta.2008.07.007.
- Courbiere B, Decanter C, Bringer-Deutsch S, Rives N, Mirallié S, Pech JC, De Ziegler D, Carré-Pigeon F, May-Panloup P, Sifer C, Amice V, Schweitzer T, Porcu-Buisson G, Poirot C (Sep 2013). "Emergency IVF for embryo freezing to preserve female fertility: a French multicentre cohort study". Human Reproduction 28 (9): 2381–8. PMID 23832792. doi:10.1093/humrep/det268.
- Roness H, Kalich-Philosoph L, Meirow D (2014). "Prevention of chemotherapy-induced ovarian damage: possible roles for hormonal and non-hormonal attenuating agents". Human Reproduction Update 20 (5): 759–774. PMID 24833728. doi:10.1093/humupd/dmu019.
- Tichelli A, Rovó A (Aug 2013). "Fertility issues following hematopoietic stem cell transplantation". Expert Review of Hematology 6 (4): 375–388. PMID 23991924. doi:10.1586/17474086.2013.816507.
In turn citing: Sanders JE, Hawley J, Levy W, Gooley T, Buckner CD, Deeg HJ, Doney K, Storb R, Sullivan K, Witherspoon R, Appelbaum FR (Apr 1996). "Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation". Blood 87 (7): 3045–3052. PMID 8639928.
- Arnon J, Meirow D, Lewis-Roness H, Ornoy A (2001). "Genetic and teratogenic effects of cancer treatments on gametes and embryos". Human Reproduction Update 7 (4): 394–403. PMID 11476352. doi:10.1093/humupd/7.4.394. 
- del Pino BM. Chemotherapy-induced Peripheral Neuropathy. NCI Cancer Bulletin. Feb 23, 2010;7(4):6.
- Grisold W, Oberndorfer S, Windebank AJ. Chemotherapy and polyneuropathies. European Association of Neurooncology Magazine. 2012;12(1).
- Beijers AJM, Jongen, JLM & Vreugdenhil1 G. . The Netherlands journal of medicine. January 2012;70(1). PMID 22271810.
- Windebank AJ & Grisold W. Chemotherapy-induced neuropathy. Journal of the Peripheral Nervous System. 2008 Mar;13(1):27–46. doi:10.1111/j.1529-8027.2008.00156.x. PMID 18346229.
- Savage L. Chemotherapy-induced pain puzzles scientists. Journal of the National Cancer Institute. 2007;99(14):1070–1071.
- Tannock IF, Ahles TA, Ganz PA, Van Dam FS (Jun 2004). "Cognitive impairment associated with chemotherapy for cancer: report of a workshop". Journal of Clinical Oncology 22 (11): 2233–9. PMID 15169812. doi:10.1200/JCO.2004.08.094.
- Wood, p. 202
- Shaikh AY, Shih JA (Jun 2012). "Chemotherapy-induced cardiotoxicity". Current Heart Failure Reports 9 (2): 117–27. PMID 22382639. doi:10.1007/s11897-012-0083-y.
- Thatishetty AV, Agresti N, O'Brien CB (Nov 2013). "Chemotherapy-induced hepatotoxicity". Clinics in Liver Disease 17 (4): 671–86, ix–x. PMID 24099024. doi:10.1016/j.cld.2013.07.010.
- King PD, Perry MC (2001). "Hepatotoxicity of chemotherapy". The Oncologist 6 (2): 162–76. PMID 11306728. doi:10.1634/theoncologist.6-2-162.
- de Jonge MJ, Verweij J (Feb 2006). "Renal toxicities of chemotherapy". Seminars in Oncology 33 (1): 68–73. PMID 16473645. doi:10.1053/j.seminoncol.2005.11.011.
- Humphreys BD, Soiffer RJ, Magee CC (Jan 2005). "Renal failure associated with cancer and its treatment: an update". Journal of the American Society of Nephrology 16 (1): 151–61. PMID 15574506. doi:10.1681/ASN.2004100843.
- Brock PR, Knight KR, Freyer DR, Campbell KC, Steyger PS, Blakley BW, Rassekh SR, Chang KW, Fligor BJ, Rajput K, Sullivan M, Neuwelt EA (Jul 2012). "Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale". Journal of Clinical Oncology 30 (19): 2408–17. PMC 3675696. PMID 22547603. doi:10.1200/JCO.2011.39.1110.
- Rybak LP, Mukherjea D, Jajoo S, Ramkumar V (Nov 2009). "Cisplatin ototoxicity and protection: clinical and experimental studies". The Tohoku Journal of Experimental Medicine 219 (3): 177–86. PMC 2927105. PMID 19851045. doi:10.1620/tjem.219.177.
- Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, Schrag D (Oct 2012). "Patients' expectations about effects of chemotherapy for advanced cancer". The New England Journal of Medicine 367 (17): 1616–25. PMC 3613151. PMID 23094723. doi:10.1056/NEJMoa1204410.
- Deeken JF, Löscher W (Mar 2007). "The blood-brain barrier and cancer: transporters, treatment, and Trojan horses". Clinical Cancer Research 13 (6): 1663–74. PMID 17363519. doi:10.1158/1078-0432.CCR-06-2854.
- Agarwala SS, Kirkwood JM (2000). "Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma". The Oncologist 5 (2): 144–51. PMID 10794805. doi:10.1634/theoncologist.5-2-144.
- Gerstner ER, Fine RL (Jun 2007). "Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm". Journal of Clinical Oncology 25 (16): 2306–12. PMID 17538177. doi:10.1200/JCO.2006.10.0677.
- Minchinton AI, Tannock IF (Aug 2006). "Drug penetration in solid tumours". Nature Reviews. Cancer 6 (8): 583–92. PMID 16862189. doi:10.1038/nrc1893.
- Nastoupil LJ, Rose AC, Flowers CR (May 2012). "Diffuse large B-cell lymphoma: current treatment approaches". Oncology 26 (5): 488–95. PMID 22730604.
- Freedman A (Oct 2012). "Follicular lymphoma: 2012 update on diagnosis and management". American Journal of Hematology 87 (10): 988–95. PMID 23001911. doi:10.1002/ajh.23313.
- Rampling R, James A, Papanastassiou V (Jun 2004). "The present and future management of malignant brain tumours: surgery, radiotherapy, chemotherapy". Journal of Neurology, Neurosurgery, and Psychiatry. 75 Suppl 2 (Suppl 2): ii24–30. PMC 1765659. PMID 15146036. doi:10.1136/jnnp.2004.040535.
- Madan V, Lear JT, Szeimies RM (Feb 2010). "Non-melanoma skin cancer". Lancet 375 (9715): 673–85. PMID 20171403. doi:10.1016/S0140-6736(09)61196-X.
- Goldman B (Feb 2003). "Multidrug resistance: can new drugs help chemotherapy score against cancer?". Journal of the National Cancer Institute 95 (4): 255–7. PMID 12591977. doi:10.1093/jnci/95.4.255.
- E. Crowley, CA. McDevitt, R. Callaghan (2009). Multidrug Resistance in Cancer. Generating Inhibitors of P-Glycoprotein: Where to, Now?. Springer Protocols. pp. 405–432.
- Luqmani YA (2005). "Mechanisms of drug resistance in cancer chemotherapy". Medical Principles and Practice. 14 Suppl 1: 35–48. PMID 16103712. doi:10.1159/000086183.
- Gerber DE (Feb 2008). "Targeted therapies: a new generation of cancer treatments". American Family Physician 77 (3): 311–9. PMID 18297955.
- Allen TM (Oct 2002). "Ligand-targeted therapeutics in anticancer therapy". Nature Reviews. Cancer 2 (10): 750–63. PMID 12360278. doi:10.1038/nrc903.
- Chen HX, Cleck JN (Aug 2009). "Adverse effects of anticancer agents that target the VEGF pathway". Nature Reviews. Clinical Oncology 6 (8): 465–77. PMID 19581909. doi:10.1038/nrclinonc.2009.94.
- Zhang J, Yang PL, Gray NS (Jan 2009). "Targeting cancer with small molecule kinase inhibitors". Nature Reviews. Cancer 9 (1): 28–39. PMID 19104514. doi:10.1038/nrc2559.
- Chidambaram M, Manavalan R, Kathiresan K (2011). "Nanotherapeutics to overcome conventional cancer chemotherapy limitations". Journal of Pharmacy & Pharmaceutical Sciences 14 (1): 67–77. PMID 21501554.
- Teicher BA, Chari RV (Oct 2011). "Antibody conjugate therapeutics: challenges and potential". Clinical Cancer Research 17 (20): 6389–97. PMID 22003066. doi:10.1158/1078-0432.CCR-11-1417.}
- Sievers EL, Linenberger M (Nov 2001). "Mylotarg: antibody-targeted chemotherapy comes of age". Current Opinion in Oncology 13 (6): 522–7. PMID 11673694. doi:10.1097/00001622-200111000-00016.
- FDA. "Mylotarg (gemtuzumab ozogamicin): Market Withdrawal". Retrieved 18 August 2013.
- Vines T, Faunce T (May 2009). "Assessing the safety and cost-effectiveness of early nanodrugs". Journal of Law and Medicine 16 (5): 822–45. PMID 19554862.
- Heller R, Gilbert R, Jaroszeski MJ (Jan 1999). "Clinical applications of electrochemotherapy". Advanced Drug Delivery Reviews 35 (1): 119–129. PMID 10837693. doi:10.1016/S0169-409X(98)00067-2.
- Larkin JO, Collins CG, Aarons S, Tangney M, Whelan M, O'Reily S, Breathnach O, Soden DM, O'Sullivan GC (Mar 2007). "Electrochemotherapy: aspects of preclinical development and early clinical experience". Annals of Surgery 245 (3): 469–479. PMC 1877027. PMID 17435555. doi:10.1097/01.sla.0000250419.36053.33.
- Marty M, Sersa G, Garbay JR, Gehl J, Collins CG, Snoj M, Billard V, Geertsen PF, Larkin JO, Miklavcic D, Pavlovic I, Paulin-Kosir SM, Cemazar M, Morsli N, Soden DM, Rudolf Z, Robert C, O'Sullivan GC, Mir LM (2006). "Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases". Eur J Cancer Suppl 4 (11): 3–13. doi:10.1016/j.ejcsup.2006.08.002.
- Möller MG, Salwa S, Soden DM, O'Sullivan GC (Nov 2009). "Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma". Expert Review of Anticancer Therapy 9 (11): 1611–1630. PMID 19895245. doi:10.1586/era.09.129.
- Testori A, Tosti G, Martinoli C, Spadola G, Cataldo F, Verrecchia F, Baldini F, Mosconi M, Soteldo J, Tedeschi I, Passoni C, Pari C, Di Pietro A, Ferrucci PF (2010). "Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach". Dermatologic Therapy 23 (6): 651–661. PMID 21054709. doi:10.1111/j.1529-8019.2010.01370.x.
- Hampton T (Feb 2011). "Electric pulses help with chemotherapy, may open new paths for other agents". Jama 305 (6): 549–551. PMID 21304073. doi:10.1001/jama.2011.92.
- Mir LM, Gehl J, Sersa G, Collins CG, Garbay JR, Billard V, Geertsen PF, Rudolf Z, O'Sullivan GC, Marty M (2006). "Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes". Eur J Cancer Suppl 4 (11): 14–25. doi:10.1016/j.ejcsup.2006.08.003.
- Soden DM, Larkin JO, Collins CG, Tangney M, Aarons S, Piggott J, Morrissey A, Dunne C, O'Sullivan GC (Feb 2006). "Successful application of targeted electrochemotherapy using novel flexible electrodes and low dose bleomycin to solid tumours". Cancer Letters 232 (2): 300–310. PMID 15964138. doi:10.1016/j.canlet.2005.03.057.
- Miklavcic D, Snoj M, Zupanic A, Kos B, Cemazar M, Kropivnik M, Bracko M, Pecnik T, Gadzijev E, Sersa G (2010). "Towards treatment planning and treatment of deep-seated solid tumors by electrochemotherapy". Biomedical Engineering Online 9 (1): 10. PMC 2843684. PMID 20178589. doi:10.1186/1475-925X-9-10.
- Issels, R. (1999). "Hyperthermia Combined with Chemotherapy – Biological Rationale, Clinical Application, and Treatment Results". Onkologie 22 (5): 374–381. doi:10.1159/000026986.
- Ben-Ari ET (Apr 2004). "Dual purpose: some cancer therapies used to treat autoimmune diseases". Journal of the National Cancer Institute 96 (8): 577–9. PMID 15100330. doi:10.1093/jnci/96.8.577.
- Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH (Aug 2001). "Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis". Annals of the Rheumatic Diseases 60 (8): 729–35. PMC 1753808. PMID 11454634. doi:10.1136/ard.60.8.729.
- Montaudié H, Sbidian E, Paul C, Maza A, Gallini A, Aractingi S, Aubin F, Bachelez H, Cribier B, Joly P, Jullien D, Le Maître M, Misery L, Richard MA, Ortonne JP (May 2011). "Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity". Journal of the European Academy of Dermatology and Venereology. 25 Suppl 2: 12–8. PMID 21388454. doi:10.1111/j.1468-3083.2011.03991.x.
- Chen J, Veras MM, Liu C, Lin J (2013). Chen, Junmin, ed. "Methotrexate for ankylosing spondylitis". The Cochrane Database of Systematic Reviews 2: CD004524. PMID 23450553. doi:10.1002/14651858.CD004524.pub4.
- Gray O, McDonnell GV, Forbes RB (2004). Gray, Orla, ed. "Methotrexate for multiple sclerosis". The Cochrane Database of Systematic Reviews (2): CD003208. PMID 15106195. doi:10.1002/14651858.CD003208.pub2.
- Gray OM, McDonnell GV, Forbes RB (Aug 2006). "A systematic review of oral methotrexate for multiple sclerosis". Multiple Sclerosis 12 (4): 507–10. PMID 16900766. doi:10.1191/1352458506ms1299oa.
- Ntali S, Bertsias G, Boumpas DT (Jun 2011). "Cyclophosphamide and lupus nephritis: when, how, for how long?". Clinical Reviews in Allergy & Immunology 40 (3): 181–91. PMID 20107927. doi:10.1007/s12016-009-8196-0.
- "NCCN Guidelines: Systemic Light Chain Amyloidosis" (PDF). National Comprehensive Cancer Network.
- Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, Horowitz M (Dec 2009). "Defining the intensity of conditioning regimens: working definitions". Biology of Blood and Marrow Transplantation 15 (12): 1628–33. PMC 2861656. PMID 19896087. doi:10.1016/j.bbmt.2009.07.004.
- "NIOSH Occupational Exposure to Antineoplastic Agents". United States National Institute for Occupational Safety and Health. Retrieved 10 October 2007.
- Connor, Thomas H. (March 7, 2011). "Hazardous Drugs in Healthcare". NIOSH: Workplace Safety and Health. Medscape & NIOSH.
- Wood, p. 38.
- McKnight JA (May 2003). "Principles of chemotherapy". Clinical Techniques in Small Animal Practice 18 (2): 67–72. PMID 12831063. doi:10.1053/svms.2003.36617.
- Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.
- Joint Formulary Committee (2013). British National Formulary (BNF) (65 ed.). London, UK: Pharmaceutical Press. ISBN 978-0-85711-084-8.
- Brunton LL, Chabner B, Knollmann BC, eds. (2011). Goodman & Gilman's The Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill. ISBN 978-0-07-162442-8.
- Alldredge BK, Corelli RL, Ernst ME, Guglielmo BJ, Jacobson PA, Kradjan WA, Williams BR (February 2012). Applied therapeutics: the clinical use of drugs. Koda Kimble and Youngs Applied Therapeutics (10th ed.). Baltimore, MD: Lippincott Williams & Wilkins. ISBN 978-1-60913-713-7.
- Sweetman, S (ed.). Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press. Retrieved 8 February 2014.
- Momparler RL (August 2012). "A Perspective on the Comparative Antileukemic Activity of 5-Aza-2'-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)". Pharmaceuticals 5 (8): 875–881. PMC 3763670. PMID 24280679. doi:10.3390/ph5080875.
- Estey EH (Sep 2013). "Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia". Leukemia 27 (9): 1803–1812. PMID 23757301. doi:10.1038/leu.2013.173.
- Kim YJ, Jang JH, Kwak JY, Lee JH, Kim HJ (Jun 2013). "Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations" (PDF). Blood Research 48 (2): 87–98. PMC 3698413. PMID 23826577. doi:10.5045/br.2013.48.2.87.
- Platzbecker U, Germing U (Sep 2013). "Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?". Leukemia 27 (9): 1813–9. PMID 23644421. doi:10.1038/leu.2013.140.
- Ritchie EK (2012). "Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome". Clinical Interventions in Aging 7: 165–73. PMC 3393359. PMID 22791989. doi:10.2147/CIA.S24659.
- Keating GM (May 2012). "Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia". Drugs 72 (8): 1111–36. PMID 22571445. doi:10.2165/11209430-000000000-00000.
- Martínez-Francés A (Jun 2011). "Adverse effects of azacitidine: onset, duration, and treatment". Advances in Therapy. 28 Suppl 4: 1–5. PMID 21688206. doi:10.1007/s12325-011-0021-5.
- Font P (Mar 2011). "Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia". Advances in Therapy. 28 Suppl 3: 1–9. PMID 21431628. doi:10.1007/s12325-011-0002-8.
- Vigil CE, Martin-Santos T, Garcia-Manero G (24 September 2010). "Safety and efficacy of azacitidine in myelodysplastic syndromes". Drug Design, Development and Therapy 4: 221–9. PMC 2948932. PMID 20957213. doi:10.2147/DDDT.S3143.
- McCormack SE, Warlick ED (7 September 2010). "Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine". OncoTargets and Therapy 3: 157–65. PMC 2939768. PMID 20856790. doi:10.2147/OTT.S5852.
- Martens, UM, ed. (2010). "11 5-Azacytidine/Azacitidine". Small molecules in oncology. Recent Results in Cancer Research 184. Heidelberg: Springer. pp. 159–170. ISBN 978-3-642-01222-8. doi:10.1007/978-3-642-01222-8.
- Chintala, L; Vaka, S; Baranda, J; Williamson, SK (9 April 2011). "Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now?" (PDF). Oncology Reviews 5 (2): 129–140. doi:10.1007/s12156-011-0074-3.
- Bang YJ (Dec 2011). "Capecitabine in gastric cancer". Expert Review of Anticancer Therapy 11 (12): 1791–1806. PMID 22117147. doi:10.1586/era.11.172.
- Hirsch BR, Zafar SY (2011). "Capecitabine in the management of colorectal cancer". Cancer Management and Research 3: 79–89. PMC 3097797. PMID 21629830. doi:10.2147/CMR.S11250.
- Quidde J, Arnold D, Stein A (2012). "Clinical management of localized colon cancer with capecitabine". Clinical Medicine Insights. Oncology 6: 363–73. PMC 3498969. PMID 23170068. doi:10.4137/CMO.S8194.
- Fernández-Martos C, Nogué M, Cejas P, Moreno-García V, Machancoses AH, Feliu J (May 2012). "The role of capecitabine in locally advanced rectal cancer treatment: an update". Drugs 72 (8): 1057–1073. PMID 22621694. doi:10.2165/11633870-000000000-00000.
- Ma Y, Tang L, Wang HX, Xu YC, Ma Y, Zhang FC (Jun 2012). "Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity". Journal of Clinical Pharmacy and Therapeutics 37 (3): 266–275. PMID 21950464. doi:10.1111/j.1365-2710.2011.01289.x.
- O'Shaughnessy JA, Kaufmann M, Siedentopf F, Dalivoust P, Debled M, Robert NJ, Harbeck N (2012). "Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer". The Oncologist 17 (4): 476–84. PMC 3336834. PMID 22418569. doi:10.1634/theoncologist.2011-0281.
- Petrelli F, Cabiddu M, Barni S (Jun 2012). "5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials". Medical Oncology 29 (2): 1020–1029. PMID 21516482. doi:10.1007/s12032-011-9958-0.
- Barrios, CH (26 January 2012). "The Role of Capecitabine in Early Stage Breast Cancer". Current Breast Cancer Reports 4 (1): 22–29. doi:10.1007/s12609-011-0067-z.
- Comi G, Hartung HP, Kurukulasuriya NC, Greenberg SJ, Scaramozza M (Jan 2013). "Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis". Expert Opinion on Pharmacotherapy 14 (1): 123–36. PMID 23256518. doi:10.1517/14656566.2013.754012.
- Spurgeon S, Yu M, Phillips JD, Epner EM (Aug 2009). "Cladribine: not just another purine analogue?". Expert Opinion on Investigational Drugs 18 (8): 1169–81. PMID 19604118. doi:10.1517/13543780903071038.
- Bagnato, F; Pirko, I (October 2011). "Novel Agents and Emerging Treatment Strategies in Multiple Sclerosis. What Role for Cladribine?". Clinical Medicine Insights: Therapeutics: 425. doi:10.4137/CMT.S6456.
- Leist TP, Weissert R (January–February 2011). "Cladribine: mode of action and implications for treatment of multiple sclerosis". Clinical Neuropharmacology 34 (1): 28–35. PMID 21242742. doi:10.1097/WNF.0b013e318204cd90.
- Warnke C, Wiendl H, Hartung HP, Stüve O, Kieseier BC (21 July 2010). "Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine". Drug Design, Development and Therapy 4: 117–26. PMC 2915536. PMID 20689698. doi:10.2147/DDDT.S6627.
- Sigal DS, Miller HJ, Schram ED, Saven A (Oct 2010). "Beyond hairy cell: the activity of cladribine in other hematologic malignancies" (PDF). Blood 116 (16): 2884–96. PMID 20634380. doi:10.1182/blood-2010-02-246140.
- Sipe JC (Mar 2010). "Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis". Expert Review of Neurotherapeutics 10 (3): 365–75. PMID 20187859. doi:10.1586/ern.10.12.
- Hartung HP, Aktas O, Kieseier B, Giancarlo Comi GC (Feb 2010). "Development of oral cladribine for the treatment of multiple sclerosis". Journal of Neurology 257 (2): 163–70. PMID 19921304. doi:10.1007/s00415-009-5359-0.
- Warnke C, Leussink VI, Goebels N, Aktas O, Boyko A, Kieseier BC, Hartung HP (Jan 2012). "Cladribine as a therapeutic option in multiple sclerosis". Clinical Immunology 142 (1): 68–75. PMID 21733757. doi:10.1016/j.clim.2011.05.009.
- Warnke C, Wiendl H, Hartung HP, Stüve O, Kieseier BC (21 July 2010). "Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine". Drug Design, Development and Therapy 4: 117–126. PMC 2915536. PMID 20689698. doi:10.2147/DDDT.S6627.
- Bryson HM, Sorkin EM (Nov 1993). "Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies". Drugs 46 (5): 872–894. PMID 7507037. doi:10.2165/00003495-199346050-00007.
- Robak T, Korycka A, Robak E (Jan 2006). "Older and new formulations of cladribine. Pharmacology and clinical efficacy in hematological malignancies". Recent Patents on Anti-Cancer Drug Discovery 1 (1): 23–38. PMID 18221024. doi:10.2174/157489206775246467.
- Hentosh P, Peffley DM (Jan 2010). "The cladribine conundrum: deciphering the drug's mechanism of action". Expert Opinion on Drug Metabolism & Toxicology 6 (1): 75–81. PMID 19968576. doi:10.1517/17425250903393745.
- Warnke C, Leussink VI, Goebels N, Aktas O, Boyko A, Kieseier BC, Hartung HP (Jan 2012). "Cladribine as a therapeutic option in multiple sclerosis". Clinical Immunology 142 (1): 68–75. PMID 21733757. doi:10.1016/j.clim.2011.05.009.
- Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S (Oct 2007). "Clofarabine: past, present, and future". Leukemia & Lymphoma 48 (10): 1922–30. PMID 17852710. doi:10.1080/10428190701545644.
- Harned TM, Gaynon PS (Apr 2008). "Treating refractory leukemias in childhood, role of clofarabine". Therapeutics and Clinical Risk Management 4 (2): 327–36. PMC 2504075. PMID 18728851. doi:10.2147/TCRM.S2941 (inactive 2015-04-14).
- Thomas X, Raffoux E, Elhamri M, Lobe I, Cannas G, Dombret H (Oct 2009). "Clofarabine for the treatment of adult acute myeloid leukemia". Future Oncology 5 (8): 1197–210. PMID 19852733. doi:10.2217/fon.09.105.
- Lech-Maranda E, Korycka A, Robak T (Jun 2009). "Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity". Mini Reviews in Medicinal Chemistry 9 (7): 805–812. PMID 19519505. doi:10.2174/138955709788452586.
- Jeha S (Oct 2009). "Recent progress in the treatment of acute lymphoblastic leukemia: clofarabine". Hematology/Oncology Clinics of North America 23 (5): 1137–44, viii. PMID 19825457. doi:10.1016/j.hoc.2009.07.011.
- Sampat K, Kantarjian H, Borthakur G (Oct 2009). "Clofarabine: emerging role in leukemias". Expert Opinion on Investigational Drugs 18 (10): 1559–1564. PMID 19715446. doi:10.1517/13543780903173222.
- Larson ML, Venugopal P (Jun 2009). "Clofarabine: a new treatment option for patients with acute myeloid leukemia". Expert Opinion on Pharmacotherapy 10 (8): 1353–1357. PMID 19463072. doi:10.1517/14656560902997990.
- Ghanem H, Jabbour E, Faderl S, Ghandhi V, Plunkett W, Kantarjian H (Feb 2010). "Clofarabine in leukemia". Expert Review of Hematology 3 (1): 15–22. PMID 21082931. doi:10.1586/ehm.09.70.
- Ghanem H, Kantarjian H, Ohanian M, Jabbour E (Apr 2013). "The role of clofarabine in acute myeloid leukemia". Leukemia & Lymphoma 54 (4): 688–698. ISBN 978-0-12-374340-4. PMID 22957815. doi:10.3109/10428194.2012.726722.
- Ghanem H, Kantarjian H, Ohanian M, Jabbour E (Apr 2013). "The role of clofarabine in acute myeloid leukemia". Leukemia & Lymphoma 54 (4): 688–698. PMID 22957815. doi:10.3109/10428194.2012.726722.
- Hamada A, Kawaguchi T, Nakano M (2002). "Clinical pharmacokinetics of cytarabine formulations". Clinical Pharmacokinetics 41 (10): 705–718. PMID 12162758. doi:10.2165/00003088-200241100-00002.
- Cros E, Jordheim L, Dumontet C, Galmarini CM (Jun 2004). "Problems related to resistance to cytarabine in acute myeloid leukemia". Leukemia & Lymphoma 45 (6): 1123–1132. PMID 15359991. doi:10.1080/1042819032000159861.
- El-Subbagh HI, Al-Badr AA (2009). "2 Cytarabine". In Brittain HG. Profiles of drug substances, excipients and related methodology (PDF). London: Academic. pp. 37–113. ISBN 978-0-12-374340-4. ISSN 0099-5428. doi:10.1016/S0099-5428(08)00002-6.
- "Dacogen (decitabine) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 10 February 2014.
- Bock HA, Gallati H, Zürcher RM, Bachofen M, Mihatsch MJ, Landmann J, Thiel G (Mar 1995). "A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation". Transplantation 59 (6): 1472–1481. PMID 7701577. doi:10.1080/10428190701471981.
- Oki Y, Aoki E, Issa JP (Feb 2007). "Decitabine--bedside to bench". Critical Reviews in Oncology/Hematology 61 (2): 140–152. PMID 17023173. doi:10.1016/j.critrevonc.2006.07.010.
- Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H (Jun 2008). "Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies" (PDF). Cancer 112 (11): 2341–51. PMID 18398832. doi:10.1002/cncr.23463.
- Santos FP, Kantarjian H, Garcia-Manero G, Issa JP, Ravandi F (Jan 2010). "Decitabine in the treatment of myelodysplastic syndromes". Expert Review of Anticancer Therapy 10 (1): 9–22. PMC 2376088. PMID 20014881. doi:10.1586/era.09.164.
- Daskalakis M, Blagitko-Dorfs N, Hackanson B (2010). "Decitabine". Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer. Recent Results in Cancer Research 184: 131–57. ISBN 978-3-642-01221-1. PMID 20072836. doi:10.1007/978-3-642-01222-8_10.
- Marks PW (Mar 2012). "Decitabine for acute myeloid leukemia". Expert Review of Anticancer Therapy 12 (3): 299–305. PMID 22369322. doi:10.1586/era.11.207.
- Garcia JS, Jain N, Godley LA (June 2010). "An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes". OncoTargets and Therapy 3: 1–13. PMC 2895778. PMID 20616953. doi:10.2147/OTT.S7222.
- Curran MP (Jun 2013). "Decitabine: a review of its use in older patients with acute myeloid leukaemia". Drugs & Aging 30 (6): 447–458. PMID 23580320. doi:10.1007/s40266-013-0084-x.
- "FUDR (floxuridine) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 10 February 2014.
- Montillo M, Ricci F, Tedeschi A (Sep 2006). "Role of fludarabine in hematological malignancies". Expert Review of Anticancer Therapy 6 (9): 1141–61. PMID 17020450. doi:10.1586/14737220.127.116.111.
- Anderson VR, Perry CM (2007). "Fludarabine: a review of its use in non-Hodgkin's lymphoma". Drugs 67 (11): 1633–55. PMID 17661532. doi:10.2165/00003495-200767110-00008.
- Ricci F, Tedeschi A, Morra E, Montillo M (Feb 2009). "Fludarabine in the treatment of chronic lymphocytic leukemia: a review". Therapeutics and Clinical Risk Management 5 (1): 187–207. PMC 2697528. PMID 19436622. doi:10.2147/TCRM.S3688.
- Souchet-Compain L, Nguyen S, Choquet S, Leblond V (Jun 2013). "Fludarabine in Waldenstrom's macroglobulinemia". Expert Review of Hematology 6 (3): 229–37. PMID 23782076. doi:10.1586/ehm.13.17.
- Plosker GL, Figgitt DP (2003). "Oral fludarabine". Drugs 63 (21): 2317–23. PMID 14524733. doi:10.2165/00003495-200363210-00004.
- Lukenbill J, Kalaycio M (Sep 2013). "Fludarabine: a review of the clear benefits and potential harms". Leukemia Research 37 (9): 986–94. PMID 23787174. doi:10.1016/j.leukres.2013.05.004.
- Grem JL (Nov 2000). "5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development". Investigational New Drugs 18 (4): 299–313. PMID 11081567. doi:10.1023/A:1006416410198.
- Abraham LM, Selva D, Casson R, Leibovitch I (2007). "The clinical applications of fluorouracil in ophthalmic practice". Drugs 67 (2): 237–55. PMID 17284086. doi:10.2165/00003495-200767020-00005.
- Patel PA (Apr 2011). "Evolution of 5-fluorouracil-based chemoradiation in the management of rectal cancer". Anti-Cancer Drugs 22 (4): 311–6. PMID 21301320. doi:10.1097/CAD.0b013e3283441a63.
- Noble S, Goa KL (Sep 1997). "Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer". Drugs 54 (3): 447–472. PMID 9279506. doi:10.2165/00003495-199754030-00009.
- Aapro MS, Martin C, Hatty S (Mar 1998). "Gemcitabine--a safety review". Anti-Cancer Drugs 9 (3): 191–201. PMID 9625429. doi:10.1097/00001813-199803000-00001.
- Ryan CW, Vogelzang NJ (Mar 2000). "Gemcitabine in the treatment of bladder cancer". Expert Opinion on Pharmacotherapy 1 (3): 547–553. PMID 11249537. doi:10.1517/14656518.104.22.1687.
- Manegold C, Zatloukal P, Krejcy K, Blatter J (Feb 2000). "Gemcitabine in non-small cell lung cancer (NSCLC)". Investigational New Drugs 18 (1): 29–42. PMID 10830139. doi:10.1023/A:1006327729228.
- Oettle H, Arnold D, Hempel C, Riess H (Nov 2000). "The role of gemcitabine alone and in combination in the treatment of pancreatic cancer". Anti-Cancer Drugs 11 (10): 771–86. PMID 11142685. doi:10.1097/00001813-200011000-00001.
- Crinò L, Cappuzzo F (Jun 2002). "Gemcitabine in non-small cell lung cancer". Expert Opinion on Pharmacotherapy 3 (6): 745–753. PMID 12036414. doi:10.1517/14656522.214.171.1245.
- Wong A, Soo RA, Yong WP, Innocenti F (2009). "Clinical pharmacology and pharmacogenetics of gemcitabine". Drug Metabolism Reviews 41 (2): 77–88. PMID 19514966. doi:10.1080/03602530902741828.
- Lennard L (October 1992). "The clinical pharmacology of 6-mercaptopurine". European Journal of Clinical Pharmacology 43 (4): 329–339. PMID 1451710. doi:10.1007/BF02220605.
- Bradford K, Shih DQ (Oct 2011). "Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease". World Journal of Gastroenterology 17 (37): 4166–73. PMC 3208360. PMID 22072847. doi:10.3748/wjg.v17.i37.4166.
- Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK (12 September 2012). "Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis". The Cochrane Database of Systematic Reviews 9: CD000478. PMID 22972046. doi:10.1002/14651858.CD000478.pub3.
- "Arranon (nelarabine) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 11 February 2014.
- Reilly KM, Kisor DF (February 2009). "Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia". OncoTargets and Therapy 2: 219–28. PMC 2886323. PMID 20616909.
- DeAngelo DJ (Oct 2009). "Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma". Hematology/Oncology Clinics of North America 23 (5): 1121–35, vii–viii. PMID 19825456. doi:10.1016/j.hoc.2009.07.008.
- Roecker AM, Stockert A, Kisor DF (December 2010). "Nelarabine in the treatment of refractory T-cell malignancies". Clinical Medicine Insights. Oncology 4: 133–41. PMC 2999959. PMID 21151585. doi:10.4137/CMO.S4364.
- Sanford M, Lyseng-Williamson KA (2008). "Nelarabine". Drugs 68 (4): 439–47. PMID 18318562. doi:10.2165/00003495-200868040-00004.
- Gandhi V, Plunkett W (Nov 2006). "Clofarabine and nelarabine: two new purine nucleoside analogs". Current Opinion in Oncology 18 (6): 584–90. PMID 16988579. doi:10.1097/01.cco.0000245326.65152.af.
- Curbo S, Karlsson A (Sep 2006). "Nelarabine: a new purine analog in the treatment of hematologic malignancies". Reviews on Recent Clinical Trials 1 (3): 185–92. PMID 18473971. doi:10.2174/157488706778250104.
- Kline J, Larson RA (Sep 2006). "Nelarabine in the treatment of refractory T-cell malignant diseases". Expert Opinion on Pharmacotherapy 7 (13): 1791–9. PMID 16925505. doi:10.1517/146565126.96.36.1991.
- Grever MR, Doan CA, Kraut EH (Mar 2003). "Pentostatin in the treatment of hairy-cell leukemia". Best Practice & Research. Clinical Haematology 16 (1): 91–9. PMID 12670468. doi:10.1016/S1521-6926(03)00002-1.
- Higman M, Vogelsang GB, Chen A (Dec 2004). "Pentostatin – pharmacology, immunology, and clinical effects in graft-versus-host disease". Expert Opinion on Pharmacotherapy 5 (12): 2605–2613. PMID 15571477. doi:10.1517/146565188.8.131.5205.
- Ho AD, Hensel M (Apr 2006). "Pentostatin for the treatment of indolent lymphoproliferative disorders". Seminars in Hematology 43 (2 Suppl 2): S2–10. PMID 16549110. doi:10.1053/j.seminhematol.2005.12.005.
- Grever MR (Oct 2006). "Pentostatin: impact on outcome in hairy cell leukemia". Hematology/Oncology Clinics of North America 20 (5): 1099–1108. PMID 16990110. doi:10.1016/j.hoc.2006.06.001.
- Sauter C, Lamanna N, Weiss MA (Sep 2008). "Pentostatin in chronic lymphocytic leukemia". Expert Opinion on Drug Metabolism & Toxicology 4 (9): 1217–22. PMID 18721115. doi:10.1517/17425255.4.9.1217.
- Lamanna N, Kay NE (Jun 2009). "Pentostatin treatment combinations in chronic lymphocytic leukemia". Clinical Advances in Hematology & Oncology 7 (6): 386–392. PMID 19606074.
- Wellington K, Goa KL (2001). "Oral tegafur/uracil". Drugs & Aging 18 (12): 935–48; discussion 949–50. PMID 11888348. doi:10.2165/00002512-200118120-00005.
- Takiuchi H, Ajani JA (Aug 1998). "Uracil-tegafur in gastric carcinoma: a comprehensive review". Journal of Clinical Oncology 16 (8): 2877–85. PMID 9704742.
- Ward SE, Kaltenthaler E, Cowan J, Marples M, Orr B, Seymour MT (Jul 2006). "The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer". British Journal of Cancer 95 (1): 27–34. PMC 2360498. PMID 16804526. doi:10.1038/sj.bjc.6603215.
- Casado E, Pfeiffer P, Feliu J, González-Barón M, Vestermark L, Jensen HA (Aug 2008). "UFT (tegafur-uracil) in rectal cancer". Annals of Oncology 19 (8): 1371–8. PMID 18381370. doi:10.1093/annonc/mdn067.
- Ishikawa T (May 2008). "Chemotherapy with enteric-coated tegafur/uracil for advanced hepatocellular carcinoma". World Journal of Gastroenterology 14 (18): 2797–801. PMC 2710718. PMID 18473401. doi:10.3748/wjg.14.2797.
- Oba K (Apr 2009). "Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: update of a meta-analysis". International Journal of Clinical Oncology 14 (2): 85–9. PMID 19390937. doi:10.1007/s10147-009-0877-4.
- Matt P, van Zwieten-Boot B, Calvo Rojas G, Ter Hofstede H, Garcia-Carbonero R, Camarero J, Abadie E, Pignatti F (2011). "The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP)". The Oncologist 16 (10): 1451–7. PMC 3228070. PMID 21963999. doi:10.1634/theoncologist.2011-0224.
- Estlin EJ (Dec 2001). "Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine". Cancer Treatment Reviews 27 (6): 351–63. PMID 11908928. doi:10.1053/ctrv.2002.0245.
- Elgemeie GH (2003). "Thioguanine, mercaptopurine: their analogs and nucleosides as antimetabolites". Current Pharmaceutical Design 9 (31): 2627–42. PMID 14529546. doi:10.2174/1381612033453677.
- Duley JA, Florin TH (Oct 2005). "Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides". Therapeutic Drug Monitoring 27 (5): 647–654. PMID 16175140. doi:10.1097/01.ftd.0000169061.52715.3e.
- De Bruyne R, Portmann B, Samyn M, Bansal S, Knisely A, Mieli-Vergani G, Dhawan A (Feb 2006). "Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia". Journal of Hepatology 44 (2): 407–10. PMID 16226335. doi:10.1016/j.jhep.2005.06.020.
- Seinen ML, van Asseldonk DP, Mulder CJ, de Boer NK (Sep 2010). "Dosing 6-thioguanine in inflammatory bowel disease: expert-based guidelines for daily practice" (PDF). Journal of Gastrointestinal and Liver Diseases 19 (3): 291–4. PMID 20922194.
- Tung JP, Maibach HI (Nov 1990). "The practical use of methotrexate in psoriasis". Drugs 40 (5): 697–712. PMID 2292232. doi:10.2165/00003495-199040050-00005.
- Bannwarth B, Labat L, Moride Y, Schaeverbeke T (Jan 1994). "Methotrexate in rheumatoid arthritis. An update". Drugs 47 (1): 25–50. PMID 7510620. doi:10.2165/00003495-199447010-00003.
- Barnhart K, Coutifaris C, Esposito M (Mar 2001). "The pharmacology of methotrexate". Expert Opinion on Pharmacotherapy 2 (3): 409–17. PMID 11336595. doi:10.1517/146565184.108.40.2069.
- Khan ZA, Tripathi R, Mishra B (Feb 2012). "Methotrexate: a detailed review on drug delivery and clinical aspects". Expert Opinion on Drug Delivery 9 (2): 151–69. PMID 22251428. doi:10.1517/17425247.2012.642362.
- Graber JJ, Omuro A (Jun 2011). "Pharmacotherapy for primary CNS lymphoma: progress beyond methotrexate?". CNS Drugs 25 (6): 447–57. PMID 21649446. doi:10.2165/11589030-000000000-00000.
- Dogra S, Mahajan R (Aug 2013). "Systemic methotrexate therapy for psoriasis: past, present and future". Clinical and Experimental Dermatology 38 (6): 573–588. PMID 23837932. doi:10.1111/ced.12062.
- Curtin NJ, Hughes AN (May 2001). "Pemetrexed disodium, a novel antifolate with multiple targets". The Lancet. Oncology 2 (5): 298–306. PMID 11905785. doi:10.1016/S1470-2045(00)00325-9.
- Gatzemeier U (Nov 2004). "Pemetrexed in malignant pleural mesothelioma". Oncology 18 (13 Suppl 8): 26–31. PMID 15655933.
- Sobrero A, Caprioni F, Fornarini G, Mammoliti S, Comandini D, Baldo S, Decian F (Nov 2004). "Pemetrexed in gastric cancer". Oncology 18 (13 Suppl 8): 51–5. PMID 15655938.
- Hazarika M, White RM, Booth BP, Wang YC, Ham DY, Liang CY, Rahman A, Gobburu JV, Li N, Sridhara R, Morse DE, Lostritto R, Garvey P, Johnson JR, Pazdur R (Feb 2005). "Pemetrexed in malignant pleural mesothelioma" (PDF). Clinical Cancer Research 11 (3): 982–92. PMID 15709163.
- Puto K, Garey JS (Apr 2005). "Pemetrexed therapy for malignant pleural mesothelioma". The Annals of Pharmacotherapy 39 (4): 678–83. PMID 15755794. doi:10.1345/aph.1E329.
- Villela LR, Stanford BL, Shah SR (May 2006). "Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy". Pharmacotherapy 26 (5): 641–54. PMID 16637794. doi:10.1592/phco.26.5.641.
- Goeminne H, van Meerbeeck JP (May 2006). "Pemetrexed in thoracic cancer". Expert Opinion on Pharmacotherapy 7 (7): 917–28. PMID 16634714. doi:10.1517/146565220.127.116.117.
- Monnerat C, Le Chevalier T (May 2006). "Review of the pemetrexed and gemcitabine combination in patients with advanced-stage non-small cell lung cancer" (PDF). Annals of Oncology. 17 Suppl 5: v86–90. PMID 16807472. doi:10.1093/annonc/mdj958.
- Longo-Sorbello GS, Chen B, Budak-Alpdogan T, Bertino JR (Feb 2007). "Role of pemetrexed in non-small cell lung cancer". Cancer Investigation 25 (1): 59–66. PMID 17364559. doi:10.1080/07357900601130748.
- Chattopadhyay S, Moran RG, Goldman ID (Feb 2007). "Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications". Molecular Cancer Therapeutics 6 (2): 404–417. PMID 17308042. doi:10.1158/1535-7163.MCT-06-0343.
- Meriggi F, Di Biasi B, Caliolo C, Zaniboni A (December 2007). "The potential role of pemetrexed in gastrointestinal cancer". Chemotherapy 54 (1): 1–8. PMID 18063861. doi:10.1159/000112311.
- Kulkarni PM, Chen R, Anand T, Monberg MJ, Obasaju CK (Jul 2008). "Efficacy and safety of pemetrexed in elderly cancer patients: results of an integrated analysis". Critical Reviews in Oncology/Hematology 67 (1): 64–70. PMID 18358737. doi:10.1016/j.critrevonc.2008.01.011.
- Felip E, Rosell R (Jun 2008). "Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)". Therapeutics and Clinical Risk Management 4 (3): 579–85. PMC 2500250. PMID 18827853. doi:10.2147/TCRM.S2248 (inactive 2015-04-14).
- Hsu JY, Wakelee H (Sep 2008). "Pemetrexed disodium for the treatment of NSCLC: an update". Drugs of Today 44 (9): 669–78. PMID 19137122. doi:10.1358/dot.2008.44.9.1250412 (inactive 2015-04-14).
- Peake, MD (July 2009). "Pemetrexed in the treatment of malignant pleural mesothelioma". Therapy 6 (4): 569–575. doi:10.2217/thy.09.30.
- Manegold C, Schmid-Bindert G, Pilz LR (Sep 2009). "Pemetrexed for the treatment of non-small-cell lung cancer". Expert Review of Anticancer Therapy 9 (9): 1195–209. PMID 19761423. doi:10.1586/ERA.09.97.
- Tomao F, Panici PB, Frati L, Tomao S (Dec 2009). "Emerging role of pemetrexed in ovarian cancer". Expert Review of Anticancer Therapy 9 (12): 1727–35. PMID 19954283. doi:10.1586/ERA.09.141.
- Fleeman N, Bagust A, McLeod C, Greenhalgh J, Boland A, Dundar Y, Dickson R, Tudur Smith C, Davis H, Green J, Pearson M (May 2010). "Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer". Health Technology Assessment. 14 Suppl 1: 47–53. PMID 20507803. doi:10.3310/hta14Suppl1/07.
- Fuld AD, Dragnev KH, Rigas JR (Jun 2010). "Pemetrexed in advanced non-small-cell lung cancer". Expert Opinion on Pharmacotherapy 11 (8): 1387–402. PMID 20446853. doi:10.1517/14656566.2010.482560.
- Somer, R (April 2010). "Maintenance therapy for metastatic non-small-cell lung cancer – the role of pemetrexed" (PDF). Lung Cancer: Targets and Therapy 1: 1–7. doi:10.2147/LCTT.S7105.
- Greenhalgh J, McLeod C, Bagust A, Boland A, Fleeman N, Dundar Y, Oyee J, Dickson R, Davis H, Green J, McKenna E, Pearson M (Oct 2010). "Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer". Health Technology Assessment 14 (Suppl. 2): 33–39. PMID 21047489. doi:10.3310/hta14suppl2/05.
- Gridelli C, Maione P, Rossi A, Bareschino MA, Schettino C, Sacco PC, Zeppa R (Mar 2011). "Pemetrexed in advanced non-small cell lung cancer". Expert Opinion on Drug Safety 10 (2): 311–7. PMID 21261558. doi:10.1517/14740338.2011.553281.
- Morotti M, Valenzano Menada M, Venturini PL, Mammoliti S, Ferrero S (Apr 2012). "Pemetrexed disodium in ovarian cancer treatment". Expert Opinion on Investigational Drugs 21 (4): 437–49. PMID 22324304. doi:10.1517/13543784.2012.661714.
- Argiris A, Pennella E, Koustenis A, Hossain AM, Obasaju CK (Jun 2013). "Pemetrexed in head and neck cancer: a systematic review". Oral Oncology 49 (6): 492–501. PMID 23466170. doi:10.1016/j.oraloncology.2013.01.007.
- Boons CC, VAN Tulder MW, Burgers JA, Beckeringh JJ, Wagner C, Hugtenburg JG (Sep 2013). "The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review". Anticancer Research 33 (9): 3553–61. PMID 24023280.
- Gunasekara NS, Faulds D (Mar 1998). "Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer". Drugs 55 (3): 423–35. PMID 9530547. doi:10.2165/00003495-199855030-00012.
- Clarke SJ, Beale PJ, Rivory LP (Dec 2000). "Clinical and preclinical pharmacokinetics of raltitrexed". Clinical Pharmacokinetics 39 (6): 429–443. PMID 11192475. doi:10.1517/13543718.104.22.1683.
- Caponigro F, Avallone A, Budillon A, Comella P, Comella G (Jul 2001). "Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy". Anti-Cancer Drugs 12 (6): 489–97. PMID 11459994. doi:10.1097/00001813-200107000-00001.
- Cunningham D, Zalcberg J, Maroun J, James R, Clarke S, Maughan TS, Vincent M, Schulz J, González Barón M, Facchini T (Mar 2002). "Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials". European Journal of Cancer 38 (4): 478–486. PMID 11872339. doi:10.1016/S0959-8049(01)00413-0.
- Van Cutsem E, Cunningham D, Maroun J, Cervantes A, Glimelius B (Apr 2002). "Raltitrexed: current clinical status and future directions". Annals of Oncology 13 (4): 513–522. PMID 12056700. doi:10.1093/annonc/mdf054.
- Cao S, Bhattacharya A, Durrani FA, Fakih M (Apr 2006). "Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer". Expert Opinion on Pharmacotherapy 7 (6): 687–703. PMID 16556086. doi:10.1517/14656522.214.171.1247.
- Wilson KS, Malfair Taylor SC (Nov 2009). "Raltitrexed: optimism and reality". Expert Opinion on Drug Metabolism & Toxicology 5 (11): 1447–1454. PMID 19863453. doi:10.1517/17425250903307455.
- Mulaku M, Opiyo N, Karumbi J, Kitonyi G, Thoithi G, English M (Nov 2013). "Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries". Archives of Disease in Childhood 98 (11): 908–14. PMC 3812872. PMID 23995076. doi:10.1136/archdischild-2012-302387.
- Navarra P, Preziosi P (Feb 1999). "Hydroxyurea: new insights on an old drug". Critical Reviews in Oncology/Hematology 29 (3): 249–55. PMID 10226728. doi:10.1016/S1040-8428(98)00032-8.
- Romanelli F, Pomeroy C, Smith KM (Feb 1999). "Hydroxyurea to inhibit human immunodeficiency virus-1 replication". Pharmacotherapy 19 (2): 196–204. PMID 10030769. doi:10.1592/phco.126.96.36.199913.
- Vichinsky EP (Jul 1997). "Hydroxyurea in children: present and future". Seminars in Hematology 34 (3 Suppl 3): 22–9. PMID 9317198.
- Gwilt PR, Tracewell WG (May 1998). "Pharmacokinetics and pharmacodynamics of hydroxyurea". Clinical Pharmacokinetics 34 (5): 347–358. PMID 9592619. doi:10.2165/00003088-199834050-00002.
- Ravot E, Lisziewicz J, Lori F (Dec 1999). "New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide". Drugs 58 (6): 953–963. PMID 10651384. doi:10.2165/00003495-199958060-00001.
- "Hydroxyurea" (PDF) 76. 2000.
- Banan M (Mar 2013). "Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond?". Annals of Hematology 92 (3): 289–99. PMID 23318979. doi:10.1007/s00277-012-1671-3.
- Dingli D, Tefferi A (Jun 2006). "Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia". Current Hematologic Malignancy Reports 1 (2): 69–74. PMID 20425334. doi:10.1007/s11899-006-0025-4.
- Lisziewicz J, Foli A, Wainberg M, Lori F (2003). "Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns". Drug Safety 26 (9): 605–24. PMID 12814330. doi:10.2165/00002018-200326090-00002.
- Bhatia, S (2008). "Secondary Malignancies: Therapy-Related t-MDS/AML". Medscape Reference. WebMD. Retrieved 7 February 2014.
- Shimada M, Itamochi H, Kigawa J (May 2013). "Nedaplatin: a cisplatin derivative in cancer chemotherapy". Cancer Management and Research 5: 67–76. PMC 3658440. PMID 23696716. doi:10.2147/CMAR.S35785.
- Ravandi F, Estey EH, Appelbaum FR, Lo-Coco F, Schiffer CA, Larson RA, Burnett AK, Kantarjian HM (Nov 2012). "Gemtuzumab ozogamicin: time to resurrect?" (PDF). Journal of Clinical Oncology 30 (32): 3921–3923. PMID 22987091. doi:10.1200/JCO.2012.43.0132.
- Lehnert M, Ludwig H, Zojer N (February 2009). "Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphoma". OncoTargets and Therapy 2: 199–208. PMC 2886339. PMID 20616907. doi:10.2147/ott.s3975.
- Cheson BD (2005). "The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma". BioDrugs 19 (5): 309–22. PMID 16207072. doi:10.2165/00063030-200519050-00004.
- Nabhan C, Kay NE (March 2011). "The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia". Clinical Medicine Insights. Oncology 5: 45–53. PMC 3076040. PMID 21499555. doi:10.4137/CMO.S4087.
- Osterborg A (Mar 2010). "Ofatumumab, a human anti-CD20 monoclonal antibody". Expert Opinion on Biological Therapy 10 (3): 439–49. PMID 20109133. doi:10.1517/14712590903586239.
- Sanford M, McCormack PL (May 2010). "Ofatumumab". Drugs 70 (8): 1013–1019. PMID 20481657. doi:10.2165/11203850-000000000-00000.
- Davies AJ (May 2007). "Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab". Oncogene 26 (25): 3614–3628. PMID 17530015. doi:10.1038/sj.onc.1210378.
- "Bexxar (tositumomab) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014.
- "Gilotrif (afatinib)". Medscape Reference. WebMD. Retrieved 9 February 2014.
- "Zaltrap (ziv-aflibercept) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014.
- Escudier B, Gore M (2011). "Axitinib for the management of metastatic renal cell carcinoma". Drugs in R&D 11 (2): 113–26. PMC 3585900. PMID 21679004. doi:10.2165/11591240-000000000-00000.
- "Bosulif (bosutinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014.
- Amsberg GK, Koschmieder S (March 2013). "Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia". OncoTargets and Therapy 6: 99–106. PMC 3594007. PMID 23493838. doi:10.2147/OTT.S19901.
- "Xalkori (crizotinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014.
- Forde PM, Rudin CM (Jun 2012). "Crizotinib in the treatment of non-small-cell lung cancer". Expert Opinion on Pharmacotherapy 13 (8): 1195–201. PMID 22594847. doi:10.1517/14656566.2012.688029.
- Frampton JE (Dec 2013). "Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer". Drugs 73 (18): 2031–2051. PMID 24288180. doi:10.1007/s40265-013-0142-z.
- Rothschild SI, Gautschi O (Sep 2013). "Crizotinib in the treatment of non--small-cell lung cancer". Clinical Lung Cancer 14 (5): 473–480. PMID 23790969. doi:10.1016/j.cllc.2013.04.006.
- Roskoski R (Sep 2013). "The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders". Expert Opinion on Drug Discovery 8 (9): 1165–1179. PMID 23805942. doi:10.1517/17460441.2013.813015.
- "Iclusig (ponatinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014.
- Price KE, Saleem N, Lee G, Steinberg M (August 2013). "Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia". OncoTargets and Therapy 6: 1111–8. PMC 3754816. PMID 23986642. doi:10.2147/OTT.S36980.
- "Stivarga (regorafenib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014.
- Strumberg D, Schultheis B (Jun 2012). "Regorafenib for cancer". Expert Opinion on Investigational Drugs 21 (6): 879–889. PMID 22577890. doi:10.1517/13543784.2012.684752.
- Aprile G, Macerelli M, Giuliani F (Jun 2013). "Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor". BioDrugs 27 (3): 213–224. PMID 23435872. doi:10.1007/s40259-013-0014-9.
- Shahda S, Saif MW (May 2013). "Regorafenib: from bench to bedside in colorectal cancer". Expert Review of Clinical Pharmacology 6 (3): 243–248. PMID 23656338. doi:10.1586/ecp.13.11.
- "Jakafi (ruxolitinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 10 February 2014.
- "JAKAVI® Ruxolitinib" (PDF). TGA eBusiness Services. Novartis Pharmaceuticals Australia Pty Limited. 21 January 2014.
- Kantarjian HM, Silver RT, Komrokji RS, Mesa RA, Tacke R, Harrison CN (Dec 2013). "Ruxolitinib for myelofibrosis--an update of its clinical effects" (PDF). Clinical Lymphoma, Myeloma & Leukemia 13 (6): 638–645. PMID 24238036. doi:10.1016/j.clml.2013.09.006.
- Vaddi K, Sarlis NJ, Gupta V (Nov 2012). "Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis". Expert Opinion on Pharmacotherapy 13 (16): 2397–2407. PMID 23051187. doi:10.1517/14656566.2012.732998.
- "Vandetanib dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014.
- "Targretin (bexarotene) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014.
- Matthay KK (Jan 2013). "Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption". Clinical Cancer Research 19 (2): 311–313. PMID 23209029. doi:10.1158/1078-0432.CCR-12-3313.
- "Amnesteem, Claravis (isotretinoin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014.
- "Isotretinoin 20mg capsules – Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Alliance Pharmaceuticals. 12 April 2013. Retrieved 9 February 2014.
- Miwako I, Kagechika H (Aug 2007). "Tamibarotene". Drugs of Today 43 (8): 563–8. PMID 17925887. doi:10.1358/dot.2007.43.8.1072615.
- Fukasawa H, Nakagomi M, Yamagata N, Katsuki H, Kawahara K, Kitaoka K, Miki T, Shudo K (2012). "Tamibarotene: a candidate retinoid drug for Alzheimer's disease". Biological & Pharmaceutical Bulletin 35 (8): 1206–12. PMID 22863914. doi:10.1248/bpb.b12-00314.
- Takeuchi M (Mar 2006). "[Clinical experience with a new synthetic retinoid, tamibarotene (Am-80) for relapsed or refractory acute promyelocytic leukemia]". Gan to Kagaku Ryoho. Cancer & Chemotherapy (in Japanese) 33 (3): 397–401. PMID 16531727.
- "Istodax (romidepsin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 10 February 2014.
- Bellos F, Mahlknecht U (Nov 2008). "Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients". Onkologie 31 (11): 629–33. PMID 19145098. doi:10.1159/000160599.
- Blaheta RA, Nau H, Michaelis M, Cinatl J (Aug 2002). "Valproate and valproate-analogues: potent tools to fight against cancer". Current Medicinal Chemistry 9 (15): 1417–33. PMID 12173980. doi:10.2174/0929867023369763.
- Blaheta RA, Cinatl J (Sep 2002). "Anti-tumor mechanisms of valproate: a novel role for an old drug". Medicinal Research Reviews 22 (5): 492–511. PMID 12210556. doi:10.1002/med.10017.
- Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA (May 2008). "Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors". Cancer Treatment Reviews 34 (3): 206–22. PMID 18226465. doi:10.1016/j.ctrv.2007.11.003.
- "Zolinza (vorinostat) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 10 February 2014.
- "Ontak (denileukin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014.
- Lansigan F, Stearns DM, Foss F (February 2010). "Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma". Cancer Management and Research 2: 53–59. PMC 3004568. PMID 21188096. doi:10.2147/CMAR.S5009.
- Manoukian G, Hagemeister F (Nov 2009). "Denileukin diftitox: a novel immunotoxin". Expert Opinion on Biological Therapy 9 (11): 1445–1451. PMID 19817678. doi:10.1517/14712590903348135.
- Kaminetzky D, Hymes KB (Dec 2008). "Denileukin diftitox for the treatment of cutaneous T-cell lymphoma". Biologics 2 (4): 717–724. PMC 2727893. PMID 19707452. doi:10.2147/BTT.S3084.
- Top 10 best-selling cancer drugs of 2013; May 29, 2014
- Rachel Airley (2009). Cancer chemotherapy. Wiley-Blackwell. ISBN 0-470-09254-8.
- Wood, Miriam; David Brighton (2005). The Royal Marsden Hospital handbook of cancer chemotherapy: a guide for the multidisciplinary team. St. Louis, Mo: Elsevier Churchill Livingstone. ISBN 0-443-07101-2.
- Fergus Macbeth; Hanna, Louise; Crosby, Tom (2008). Practical clinical oncology. Cambridge, UK: Cambridge University Press.
- Perry, Michael J. (2008). The Chemotherapy source book. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins.
- Faguet GB (2005). The War on Cancer. Springer. p. 71. ISBN 1-4020-3618-3.
- Hirsch J (Sep 2006). "An anniversary for cancer chemotherapy". Jama 296 (12): 1518–20. PMID 17003400. doi:10.1001/jama.296.12.1518.
- Huang ES (2000). Internal medicine: handbook for clinicians, resident survival guide. Arlington, VA: Scrub Hill Press. p. 130. ISBN 978-0-9645467-5-2.
- Randall, [edited by] William J. Hoskins, Carlos A. Perez, Robert C. Young, Richard R. Barakat, Maurie Markman, Marcus E. (2005). Principles and practice of gynecologic oncology (4. ed.). Baltimore, Md.: Lippincott Williams & Wilkins. pp. 93–94. ISBN 0-7817-4689-2.